swiss federation of clinical neuro-societies

4th SFCNS Congress

Swiss Federation of Clinical Neuro-Societies

Program

October 23 - 25, 2019SwissTech Convention Center, EPFLLausanne

sfcns2019.congress-imk.ch Org

aniz

ed b

y IM

K In

stitu

te fo

r med

icin

e an

d co

mm

unic

atio

n Lt

d

YEARS

OCREVUS®

Approuvé pour les formes actives de sclérose en plaques récurrente (SEP-R) et la sclérose en plaques primaire progressive (SEP-PP)1

Application simple: libre de traitement tous les 6 mois après la dose initiale*,1

Profil de sécurité et de tolérance favorable sur 5 ans1,2

Réduit l’activité inflammatoire et la progression de la maladie1

Roche Pharma (Suisse) SA4153 Reinach

* La dose initiale de 600 mg est administrée en deux perfusions i.v. distinctes, c’est-à-dire sous forme de deux perfusions de 300 mg chacune, à intervalle de deux semaines. Références: 1. Information professionnelle d’OCREVUS®, www.swissmedicinfo.ch 2. Hauser SL et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. ECTRIMS Online Library. October 2018; 229069. Abstract and Poster P1229. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/229069/stephen.l.hauser.safety.of.ocrelizumab.in.multiple.sclerosis. updated.analysis.html

OCREVUS® (ocrélizumab). Anticorps monoclonal humanisé recombinant (anti-CD20). I: Patients adultes atteints de formes actives de sclérose en plaques (SEP) récurrente. Patients adultes atteints de sclérose en plaques primaire progressive (SEP-PP) pour ralentir la progression de la maladie et réduire l’aggravation de la vitesse de marche. D: Dose initiale: 600 mg en deux perfusions i.v. de 300 mg chacune à intervalle de deux semaines. Doses suivantes: Doses uniques de 600 mg tous les 6 mois. Prémédication: 100 mg de méthylprednisolone i.v. ou équivalent et un antihistaminique avant chaque perfusion. CI: Hypersensibilité à l’ocrélizumab ou à l’un des excipients, insuffisance cardiaque sévère (stade NYHA IV), immunodépression sévère, infection active, affection active maligne existante, à l’exception des patients avec un carcinome basocellulaire début du traitement durant la grossesse. MP: Réactions liées à la perfusion: En cas de symptômes pulmonaires sévères (bronchospasme, exacerbations d’asthme) interrompre immédiatement et définitivement la perfusion; survenue d’une hypotension est possible, donc envisager l’interruption d’un traitement antihypertenseur 12 heures avant et pendant chaque perfusion d’OCREVUS. Réactions d’hypersensibilité: Peuvent se produire, mais en principe pas au cours de la première perfusion. En cas de survenue, immédiatement et définitivement arrêter la perfusion. Infections: Ne pas administrer chez les patients présentant des infections actives sévères (tuberculose, sepsis, infections opportunistes), une réponse immunitaire fortement limitée (p.ex. nombre de cellules CD4 ou CD8 considérablement réduit). Reporter l’administration jusqu’à la guérison chez les patients présentant une infection active. Le risque de LEMP sous OCREVUS ne peut pas être exclu. En cas d’une LEMP, arrêter le traitement définitivement. Réalisier un dépistage du HBV avant l’instauration d’un traitement par OCREVUS. Immunosuppresseurs: L’utilisation concomitante d’autres immunosuppresseurs à l’exception des corticostéroïdes pour le traitement symptomatique des poussées, n’est pas recommandée. Vaccinations: Contrôler le statut des vaccinations et tenir compte des recommandations en vigueur en matière de vaccinations de protection avant d’instaurer un traitement par OCREVUS. Achever la vaccination au moins 6 semaines avant la première perfusion d’OCREVUS. IA: Aucune étude formelle sur les interactions médicamenteuses n’a été réalisée. Le risque d’interaction avec des médicaments utilisés de façon concomitante ne peut être exclu. Gr/Al: Ne pas utiliser OCREVUS pendant la grossesse, à moins que le bénéfice potentiel pour la mère ne prédomine sur le risque potentiel encouru par le fœtus. Cesser l’allaitement pendant le traitement par OCREVUS. EI: Très fréquents: Réactions liées à la perfusion, infections des voies respiratoires supérieures, rhinopharyngite, grippe, taux d’IgM sériques réduits. Fréquents: Neutropénie, bronchite, sinusite, gastro-entérite, infection virale, herpès buccal, infection des voies respiratoires, cellulite, zona, conjonctivite, toux, catarrhe, taux d’IgG sériques réduits. P: 1 flacon de 10 ml contient 300 mg d’ocrélizumab. Catégorie de vente: A. Mise à jour de l’information: Août 2018. Pour toute information supplémentaire, veuillez consulter l’information professionnelle (www.swissmedicinfo.ch).

02/2019

190327_LT_953_011903_Anzeige_RA_148x210_F.indd 1 27.03.19 15:24

Overview SwissTech Convention Center, EPFL

Office ABOffice CD1

23

45

Entrance

1 Campus

Industrial Exhibition

Auditorium C

Secretariat

ePoster

2 Cloud0 Garden

0 Garden

Plenum

1 Campus

1 Campus

2 Cloud

SwissTech Convention Center, EPFL

Office ABOffice CD

Garden 1Garden 2

Garden 3Garden 4

Garden 5

Entrance

1 Campus


Secretariat

CongressLounge

Auditorium C

2 Cloud0 Garden

0 Garden

ePoster

Parallel SessionsGarden 1-5

AV-Check

Plenary Sessions

1 Campus

1 Campus

2 Cloud

Download the App

official SFCNS congress app sponsor 2019:

sfcns.mca-congress.com/iossfcns.mca-congress.com/android

IMNFKG1911 Raumubersicht A0 Hoch_01.indd 1 11.10.19 13:21

1

Contents

Welcome from the presidents 3

Short Portrait SFCNS 4

SFCNS executive board 5

General information 6-9

Abstracts 10

Travel information 11

Partner companies | Sponsors 12

Accommodation | Announcements 13

Scientific program

Wednesday | 23.10.2019 14-23

Thursday | 24.10.2019 24-41

Friday | 25.10.2019 42-51

Program SFND/ASDN 41

Program IG-NOPPS 51

Program OHBM 52-55

Meetings 57-59

ePoster 61-75

Adresses of the invited speakers and chairs 76-81

Industrial Exhibition 83

Download the App

official SFCNS congress app sponsor 2019:

https://sfcns.mca-congress.com/ioshttps://sfcns.mca-congress.com/android

Weniger Migräne.Mehr vom Leben.*,1– 5

ist genug.Genug

* Aimovig® reduzierte die Anzahl der monatlichen Migränetage und erhöhte die Lebensqualität im Vergleich zur Baseline jeweils signifi kant gegenüber Placebo.2–5

Referenzen: 1. Aimovig® Fachinformation. Stand Juli 2018. www.swissmedicinfo.ch 2. Goadsby PJ et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017;377(22):2123–2132. 3. Tepper S et al. Safety and effi cacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16(6):425–434. 4. Dodick DW et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018;38(6):1026–1037. 5. Lipton et al., Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology 2019;92(19):e2250–e2260.

Aimovig® Z: Injektionslösung zur subkutanen Anwendung (Fertigspritze und Fertigpen). 1 Fertigspritze bzw. 1 Fertigpen zu 1mL enthält 70 mg Erenumab. I: Prophylaktische Behandlung der Migräne bei Erwachsenen, sofern diese indiziert ist. D: Empfohlen wird eine Aimovig-Dosis von 70 mg als subkutane Injektion einmal monatlich. Bei Patienten, die auf diese Dosierung eine ungenügende Wirkung zeigen, kann die Dosierung auf 140 mg einmal monatlich gesteigert werden, solange dadurch eine bessere Wirkung nachweisbar ist. Detaillierte Anweisung und spezielle Patientengruppen s. www.swissmedicinfo.ch. KI: Überempfi ndlichkeit gegenüber dem Wirkstoff Erenumab oder einem der Hilfsstoffe gemäss Zusammensetzung. VM: Die abnehmbare Kappe enthält trockenen Naturkautschuklatex, der allergische Reaktionen hervorrufen kann. Die Sicherheit und Wirksamkeit von Aimovig bei Kindern und Jugendlichen ist nicht untersucht worden. Während Schwangerschaft und Stillzeit sollte Aimovig nicht angewendet werden, es sei denn dies ist eindeutig erforderlich. Einzelheiten s. www.swissmedicinfo.ch. IA: Aimovig zeigte keinen Einfl uss auf die Pharmakokinetik von Sumatriptan, sowie eines oralen Kombinationspräparats zur Empfängnisverhütung, das Ethinylestradiol und Norgestimat enthielt. Erenumab wird nicht von Cytochrom P450 Enzymen metabolisiert, daher sind Interaktionen mit Substraten, Induktoren oder Inhibitoren von Cytochrom P450-Enzymen unwahrscheinlich. Einzelheiten s. www.swissmedicinfo.ch. UW: Häufi g: Obstipation, Juckreiz, Muskelkrämpfe, Reaktionen an der Injektionsstelle (Schmerzen, Erythem oder Juckreiz). Einzelheiten s. www.swissmedicinfo.ch. P: Injektionslösung in einer Fertigspritze zu 70 mg: 1 und 2 Fertigspritzen. Injektionslösung im Fertigpen zu 70 mg: 1 und 2 Fertigpens. Verkaufskategorie: B. Weitere Informationen fi nden Sie unter www.swissmedicinfo.ch. V01 Juli 2018.

Novartis Pharma Schweiz AG, Risch; Adresse: Suurstoffi 14, 6343 Rotkreuz, Tel. 041 763 71 11

NO51

956

06/2

019

90571_O_AIM_Anzeige_SFNCS_RZ_190628.indd 1 28.06.19 10:02

Welcom

e

3

Welcome from the presidents of SFCNS and the scientific comittee

Dear Colleagues

It is our great pleasure to announce the 4th congress of the Swiss Federation of Clinical Neuro-Societies (SFCNS), which will take place in Lausanne at the SwissTech Convention Center from October 23 to 25, 2019.

Starting with the the 6 original (founding) societies (Neurology, Neurosurgery, Neuroradiology, Neurope-diatrics, Neuropathology and Clinical Neurophysiology), the federation has over the last years grown to encompass most if not all societies and individuals involved in managing diseases of the central nervous system in Switzerland.

Ever since its foundation, the SFCNS has undertaken efforts to improve the quality and visibility of Swiss neuroscience – locally, nationally and internationally. This has been done with great success by promoting clinical excellence, scientific research as well as political lobbying. Further, collaboration and exchange between the various clinical neurosocieties which form the SFCNS have been promoted.

The SFCNS has thus successfully been active in the creation and certification of world-class stroke cen-ters as well as in defining the criteria by which Highly Specialized Medicine (HSM) is to be practiced in Switzerland in the domain of clinical neurosciences. Since its founding in 2009 and the first congress in 2010, the SFCNS has continuously grown and expanded its success, vision and influence. In addition to the congress, the Society has successfully developed summer schools to attract its members and further es-tablished the Journal Clinical and Translational Neuroscience as its own vehicle for scientific publications.

One of the central factors for the success of the SFCNS is its triennial congress, which represents a unique encounter between not just the various societies which form its core but also of adjacent specialities that will contribute to our common future. Thus, it is exceedingly important that the congress does not only represent the various member societies, but that it also has a spirit of its own.

The fourth congress of the SFCNS is this time not just held in any congress center, but in the heart of Swiss technological innovation at the SwissTech Convention Center, which is located in the heart of the campus of the École polytechnique fédérale de Lausanne (EPFL). This represents a breakout from the previous locations Basel and Montreux and is of extreme importance to us all, since clinical neuroscience has benefited from advances in technology since its inception. Further, leaders in neuroscience very often con-tribute to technological developments themselves. Therefore, additionally to the traditional neuro-science participants we will see participants from fields of technologies such as basic neuroimaging, robotics and artificial intelligence that have contributed and will further contribute to the definition of the way clinical neuroscientists work over the next century.

The congress program is extremely rich and varied and proposes a multitude of formats for presenting knowledge and advances in neuroscientific areas: the days will start with plenary sessions that will be followed by satellite symposia and parallel sessions devoted to topics of clinical and scientific interest.

We hope that you will join us in Lausanne for this exciting event and that you will have as much pleasure attending the congress as we have in organizing it.

Prof. Karl Schaller, MD Prof. Karl Olof Lövblad, MD SFCNS President Congress President

SFCN

S

4

Short Portrait of SFCNS

The Swiss Federation of Clinical Neuro-Societies (SFCNS) was officially founded in 2009. So it celebrates its tenth anniversary this year. First steps in that direction were taken at the Joint Meeting of six Clinical Neuroscience Societies in April 2008 in Montreux, which commemorated the centenary of the Swiss Neu-rological Society.

Following this great success and overwhelming approval, the Swiss Neurological Society (SNS), Swiss Society of Neurosurgery (SSNS), Swiss Society of Clinical Neurophysiology (SSNC), Swiss Society of Neuropaediatrics (SSNP), Swiss Society of Neuroradiology (SSNR), and Swiss Society of Neuropathology (SSNPath) decided to close ranks and form a Swiss Federation of Clinical Neuro-Societies (SFCNS) which marked the beginning of a new cooperative effort to strengthen the clinical neurosciences in Switzerland. The federation should formalise and structure the joint medico-political, educational and clinical research efforts.

Its further aim is to hold common meetings on a regular basis to facilitate mutual interactions and be open also to other medical groups pursuing clinical neuroscience interests. It will also be a cooperative partner of the Swiss Society for Neuroscience.

For further information about the SFCNS please visit www.sfcns.ch.

Ordinary members

Swiss Neurological Society SNS | www.swissneuro.ch Swiss Society of Neurosurgery SSNS | www.swissneurosurgery.ch Swiss Society of Clinical Neurophysiology SSCN | www.sgkn.ch Swiss Society of Neuropaediatrics SSNP | www.neuropaediatrie.ch Swiss Society of Neuroradiology SSNR | www.swissneuroradiology.ch Swiss Society of Neuropathology SSNPath | www.ssn.uzh.ch Swiss Society of Biological Psychiatry SSBP | www.ssbp.ch

Associated members

Swiss Headache Society SHS | www.headache.ch Swiss Society for Neurorehabilitation SSNRehab | www.sgnr.chSwiss Association of Neuropsychology | www.neuropsy.ch Swiss Society of Behavioral Neurology SSBN | www.sgvn.ch Swiss Stroke Society SSS | www.neurovasc.ch

Extraordinary members

Swiss League Against Epilepsy | www.epi.ch aphasie suisse | www.aphasie.ch

The Swiss Society of Neuroradiology SSNR celebrates its 30th anniversary this year.

1989-2019YEARS SSNR

YEARS

SFCNS

5

SFCNS Executive Board

PresidentProf. Karl Schaller, MDDirektor und ChefarztHUG Service de NeurochirurgieRue Gabrielle-Perret-Gentil 4CH-1211 Geneva 4

Past PresidentProf. Anton Valavanis, MDLeiter klinisches NeurozentrumUniversitätsspital ZürichFrauenklinikstrasse 10CH-8091 Zurich

Vice PresidentProf. Philippe Lyrer, MDStv. Chefarzt Neurologische Klinik und Poliklinik Leiter Stroke Center Universitätsspital BaselSpitalstrasse 21CH-4056 Basel

Secretary/TreasurerProf. Barbara Tettenborn, MDChefärztin Neurologie Kantonsspital St. GallenKlinik für NeurologieCH-9007 St.Gallen

Assessor SSNRProf. Jan Gralla, MDChefarzt und DirektorDiagnostische und Interventionelle NeuroradiologieInselspital Bern CH-3010 Bern

Assessor SSNCProf. Andreas Raabe, MDDirektor und ChefarztNeurochirurgieInselspital BernCH-3010 Bern

Assessor SSNPPD Christian Korff, MDResponsable de l’unité deneuropédiatrieHUGRue Willy Donzé 6CH-1205 Geneva

Assessor SSBPProf. Martin Hatzinger, MDDirektor Psychiatrische Dienste soHWeissensteinstrasse 102CH-4503 Solothurn

Assessor SSCNProf. Kai Rösler, MDNeurozentrum BaselMarktplatz 5CH-4001 Basel

Assessor YouCliNPD Arseny Sokolov, MDNeurologie Centre hospitalier universitaire vaudois CHUVRue du Bugnon 46CH-1011 Lausanne

General SecretaryHarald F. GrossmannExecutive OwnerIMK Institute for medicine and communication Ltd.Münsterberg 1CH-4001 Basel

6

Gene

ral General Information

Date

Venue

Website

Website and Contact of SFCNS

President SFCNS

Scientific Committee

Participating professional associations

Professional Congress Organizer (PCO)

Opening hours secretariat

Opening hours industrial exhibition

23.10.-25.10.2019

SwissTech Convention Center, EPFLRoute Louis-Favre 2 | 1024 Ecublens Switzerland

sfcns2019.congress-imk.ch

Swiss Federation of Clinical Neuro-Societies SFCNS www.sfcns.ch | [email protected]

Prof. Karl Schaller, MD, Geneva

Prof. Karl Olof Lövblad, MD, Geneva, Congress PresidentBigna Bölsterli, MD, ZurichProf. Kim Q. Do Cuénod, MD, LausanneProf. Javier Fandino, MD, AarauBarbara Goeggel-Simonetti, MD, Bern/BellinzonaProf. Doron Merkler, MD, GenevaProf. Krassen Nedeltchev, MD, AarauProf. Andreas Raabe, MD, BernProf. Kai Rösler, MD, Bern/BaselProf. Andrea Rossetti, MD, LausanneProf. Christoph Stippich, MD, ZurichProf. Barbara Tettenborn, MD, St.GallenProf. Dimitri Van De Ville, PhD, LausanneProf. Sebastian Walther, MD, BernRebekka Zimmermann, MD, Bern

• Swiss Association for Neurophysiological Diagnostic SFND/ASDN (www.sfnd.ch) - with a separate programm on Thursday, 24.10.19

• Association of neurosurgical nursing staff Switzerland ANNSS (www.ig-nopps.ch) with a separate one day programm on Friday, 25.10.2019

IMK Institute for medicine and communication Ltd.Harald F. GrossmannMünsterberg 1 | CH-4001 BaselTel. +41 61 561 53 53www.imk.ch | [email protected]

Wednesday, 23.10.2019 08:30-19:00Thursday, 24.10.2019 07:30-19:00Friday, 25.10.2019 07:45-17:30

Wednesday, 23.10.2019 09:30-17:30Thursday, 24.10.2019 08:00-17:15Friday, 25.10.2019 08:15-16:00

7

General

General Information

Registration Fees 4th SFCNS Congress

Registration Fees OHBM Alpine Chapter

25.10.2019

Registration Fees SFCNS Imaging Course

26.10.2019

Cancellation Policy

Confirmation of Participation

IMK must be informed about cancellations in written form until August 31, 2019. We will be able to reimburse 50% of the congress fees. After August 31, 2019 no refunds will be made.

Participants will receive an electronic confirmation of participation per e-mail after the congress

Early Birduntil 15.9.2019

Regularfrom 16.9.2019

Combination with SFCNS Imaging Course Networking Event

1 day 3 days 1 day 3 days 4 days 24.10.2019Member physicians | Member psychologists 150 300 200 350 400 120

Non-member physicians | Non-member psychologists 200 400 250 450 500 120

Member residents, SAYN | SYNS | YouCliN | youngSVNP 60 120 80 160 180 60

Non-member residents 80 140 100 180 220 60Students, MTM 50 100 70 140 160 60SFND | IG-NOPPS* 50 80 - 60

Fees in CHF

Regular OnsiteCombination with

OHBM Alpine Chapter

Combination with3 days SFCNS

CongressMember physicians | Member psychologists 120 170 250 400

Non-member physicians | Non-member psychologists 150 200 250 500

Member residents, SAYN | SYNS | YouCliN | youngSVNP 100 150 250 180

Non-member residents 120 170 250 220Students, MTM 50 80 100 160

Fees in CHF

Regular and onsite Combination with SFCNS Imaging Course

Physicians, psychologists & residents 150 250

Students 70 100Fees in CHF

Members of the following societies may register in the category members: SNS, SSNS, SSCN, SSNP, SSNR, SSNPath, SSBP, SHS, SSNRehab, SANP, SSBN, SSS, SLaE, Aphasie Suisse, SAYN, SYNS, YouCliN, youngSVNP

*The registration fees IG-NOPPS are covered by the SSNS. Therefore the participation is free of charge.

An Alpine Chapter membership (via the organisation platform oegfmrt.org) allows up to 50% discount on the SFCNS Imaging Course and the OHBM Alpine Chapter Symposium.

Young Clinical Neuroscientists

Networking Eventstarting at 21:00

Slam Sessionstarting at 20:00

YouClin After Party 2019 with DJ Drumminsax

starting at 22:30

Thursday, 24 October 2019 Olympic Museum Lausanne

In combination with Slam Session and Networking Event. Registration requiredFor details refer to sfcns2019.congress-imk.ch O

rgan

ized

by

IMK

Inst

itute

for m

edic

ine

and

com

mun

icat

ion

Ltd


Networking EventIncluding Science Slam Session & YouCliN Party

as from 19:30 Aperitif / Visit of Museum

20:00-21:00 Slam Session

21:00 Flying Dinner

YouCliN After Party 2019 with DJ Drumminsax

starting at 22:30


Separate registration requiredFor details refer to sfcns2019.congress-imk.ch O

rgan

ized

by

IMK

Inst

itute

for m

edic

ine

and

com

mun

icat

ion

Ltd

IMNFKG19_YouClin_Party_Poster_A0_11.indd 1 11.10.19 15:15

9

General

Credits

Language

Speakers‘ Dinner

Networking Event (including Science slam

session & YouCliN Party)

The official congress language is English. Slides and presentations in the main topics have to be in English. Workshops and Parallel Sessions may be presented in English, German or French. Abstracts have to be in English.

Wednesday, 23.10.2019, 19:30 hRestaurant eat meRue Pépinet 3CH-1003 Lausanne

Thursday, 24.10.2019, 19:30 hThe Olympic Museum1, quai d‘Ouchy, 1006 Lausanne

“Science slam” session – bringing science to the stageJoin the „science slam“ session in the Auditorium of the Olympic Museum before the start of the Networking Event

YouCliN Party – For Everyone! Dance the night away with DJ Drumminsax after the Networking Event (as from 22:30 h)

Access: By metro or TL city busM2 metro line and No. 2 bus (Ouchy stop) or No. 8 or 25 (Musée Olympique stop)

For more details refer to sfcns2019.congress-imk.ch

General Information


Networking Eventstarting at 21:00

Slam Sessionstarting at 20:00

YouClin After Party 2019 with DJ Drumminsax

starting at 22:30


In combination with Slam Session and Networking Event. Registration requiredFor details refer to sfcns2019.congress-imk.ch O

rgan

ized

by

IMK

Inst

itute

for m

edic

ine

and

com

mun

icat

ion

Ltd

23.10.2019 24.10.2019 25.10.2019 TotalSwiss Neurological Society | SNS 5 7 8 20

Swiss Society for Neurosurgery | SSNS 8 8 8 24

Swiss Association of Neuropsychology 6 8 8 22

Swiss Society of Radiology | SSR 5 6 5 16

Swiss Society of Neuropaediatrics | SSNP 5 5 5 15

10

Gene

ral Abstracts

Abstract publication

Information for the speakers with ePoster

presentation

YouCliN Award

YouCliN Video

Presentation layout

ePoster submission / upload

ePoster stations

Accepted abstracts will be published in the „e.Supplementum Clinical and Translational Neuroscience CTN“ and online as abstractbook.

The lecture halls are equipped with a beamer and computer. We ask the speakers to save their presentation on a USB memory stick and take it to the „AV-Check“ at the latest one hour before the session. ePoster presentation will take place (3min presentation + 1min discussion) during the ePoster sessions on Thursday, October 24, 2019, 11:30-12:30.(SHS, SNS, SSBN, SSBP, SSCN, SSNP, SSNPath, SSNR, SSNRehab, SSNS, SSS, SANP, aphasie suisse, SLaE)

The lecture halls are equipped with a beamer and computer. We ask the speak-ers to save their presentation on a USB memory stick and take it to the „AV-Check“ at the latest one hour before the session. The YouCliN Award (8min presentation + 2min discussion) will take place on Wednesday, October 23, 2019, 16:15-17:15.

The lecture halls are equipped with a beamer and computer. We ask the speakers to save their presentation on a USB memory stick and take it to the„AV-Check“ at the latest one hour before the session. The YouCliN Video Session (in total 15 minutes) will take place on Friday, October 25, 2019, 10:15-11:15.

The slides for the ePoster presentation shall be prepared as PowerPoint pre-sentation with a format 16:9 (max. 5 slides). The slides shall be structured as follows:

1. Background / aim2. Methods3. Results4. Discussion5. Additional slide (can be used for tables, graphics, etc.)

Posters are to be designed in A0 portrait format: 118.9cm x 84.1cm (height x width), max. 3 slides. Further information and templates as well as the online submission: http://sfcns.eposters.ch.Deadline for the ePoster upload: October 1, 2019.

The ePoster stations are located in the lounge / exhibition area.

11

General

Travel information

GENÈVE

MORGESPRÉVERENGES

RENENS GARE

LAUSANNE GARE

LAUSANNE

M1

M1 / M2

M2

M2

M1

BOURDONETTE

MALADIÈRE

FLON GARE

SAINT-SULPICE

ECUBLENS

CHAVANNES-PRÈS-RENENS

Rue de Lausanne

Rue de Genève

Rue du Jura

Av. d

u Ti

r-Féd

éral

Route Cantonale

SortieEPFL-UNIL

AUTOROUTEMOTORWAY

A1AUTOROUTEMOTORWAY

A1

A1

BERN

EPFL

LAC LÉMAN

Route de la Sorge

OUCHY

SW ISSTECHCONVENTION CENTER

EPFL

By trainConvenient, quick and reliable public transportation is probably the best way to get around in Lausanne and in Switzerland. The metro M1 can bring you to the SwissTech Convention Center from the Renens train station or the city center of Lausanne. It comes every 5 minutes and it will only take you 10 minutes to get here.

Use public transportation for free!By staying in a hotel in Lausanne and paying the city tax, you gain free and unrestricted access to all of the city’s public transportation (bus, train, metro). The Lausanne Transport Card, the key to mobility is distrib-uted in every accommodation in Lausanne.

By carThe SwissTech Convention Center is 2 minutes away from the highway exit “Lausanne Sud, UNIL-EPFL”. There are 400 public parking spaces 5 minutes away walking from the STCC.

The SwissTech Convention Center is a 2 minute walk away.

Parking detailsParking Les Arcades80 places | CHF 30.- per dayUnlimited duration

By planeLausanne is very close to Geneva airport or to Zurich airport that are connected to 196 destinations worldwide.

Geneva airport is only 45 minutes away from Lausanne using a car or public transportation. Trains depart from Geneva Airport every 15 minutes. The train station is located in the airport.

Zurich airport is 2.5 hours away by car and by train. There is also a station in the airport and trains to Lausanne leave every 15 minutes.

Parking EPFL Campus car park150 places| CHF 30.- per dayUnlimited duration

Parking P+R Bourbonnette 250 places| CHF 15.- per day1 day duration

12

Gene

ral Sponsors

We would like to thank the following companies for supporting the SFCNS Congress 2019:

Diamond Partner 2019

Partner 2019

Supporter 2019

Premium Partner 2019

RAPIDMEDICAL

13

General

Announcements – Future congresses

Accommodation

For the participants of the 4th SFCNS Congress, rooms at a special rate are available at the SwissTech Hotel in Lausanne.

Participants can book their hotel room through the website swisstech-hotel.com using the keyword „IMNFKG19“.

SwissTech HotelRoute Louis Favre 10BCH-1024 Ecublens

*** SwissTech Hotel LausanneThe SwissTech Hotel welcomes you to the campus of the Swiss Federal Institute of Technology (EPFL), right next to the EPFL underground station and 100 m from the SwissTech Convention Center.

16.11.2019Inselspital Bern

23.05-26.05.2020Paris, France

11.06-12.06.2020Congress Centre Kursaal Interlaken

21.08.2020Inselspital Bern

01.10-02.10.2020BernExpo

19.11-20.11.2020Congress Centre Kursaal Interlaken

SSNR Educational Course 2019Swiss Society of Neuroradiology

SNG Sponsorpool 2020 - 6th EAN Congress

Joint Annual Meeting 2020Swiss Society of NeurosurgerySwiss Society of Neuroradiology

3rd SFCNS Summer School

Joint Annual Meeting 2020Swiss Headache SocietySwiss Association for the Study of Pain

Annual Meeting Swiss Neurological SocietyInvited society: Swiss Society of Behavioural Neurology

Wed

nesd

ay

14

Daily overview Wednesday | 23.10.2019

Auditorium C Garden 1BC Garden 2BC Garden 3BC Garden 4BC09:45 - 10:00 09:45-10:00 Opening10:00 - 10:15 10:00-10:45

Keynote Lecture10:15 - 10:3010:30 - 10:4510:45 - 11:00 10:45-11:15 Coffee Break11:00 - 11:1511:15 - 11:30 11:15-12:30

Smarter Devices11:30 - 11:4511:45 - 12:0012:00 - 12:1512:15 - 12:3012:30 - 12:45

12:30-13:15 Lunch12:45 - 13:0013:00 - 13:1513:15 - 13:30 13:15-14:15

Satellite SymposiumNovartis

13:15-14:15Satellite SymposiumAlnylam

13:15-14:00Satellite SymposiumMitsubishi Tanabe Pharma GmbH

13:30 - 13:45

13:45 - 14:00

14:00 - 14:1514:15 - 14:30 14:15-14:45 Coffee Break14:30 - 14:45

14:45 - 15:00 14:45-15:45Acute Stroke

14:45-15:45Neuro-Intensive Care

14:45-15:45YouCliN – a multidisciplinary session

14:45-15:45Advances in neurovascu-lar imaging and impact on clinical decision making

14:45-15:45Models of human memory – Part I15:00 - 15:15

15:15 - 15:3015:30 - 15:4515:45 - 16:00 15:45-16:15 Coffee Break16:00 - 16:15

16:15 - 16:30 16:15-17:15Baasch-Medicus-Lecture

16:15-17:15IntraoperativeNeuromonitoring

16:15-17:15 YouCliN-Award

16:15-17:15Models of human memory – Part II

16:15-16:45Pitfalls of misdiagnosis of DOC16:30 - 16:45

16:45 - 17:0017:00 - 17:1517:15 - 17:3017:30 - 17:45 17:30-19:00

General Assembly SNS(SNG)

17:45 - 18:0018:00 - 18:1518:15 - 18:3018:30 - 18:4518:45 - 19:0019:00 - 19:15 from 19:30 Dinner Faculty/Speakers

Plenary Session General Assembly (GA)Parallel Session Satellite Symposium

15

15

15 17 17

17 19 19 19 19

2323212121

23

Wednesday

15

Program, Wednesday | 23.10.2019

09:45-10:00 Congress OpeningKarl-Olof Lövblad | Karl Schaller, Geneva, CH

10:00-10:45 Auditorium C

Keynote Lecture Chair: Claudio Bassetti, Bern, CH

Presence Hallucinations: from Epilepsy and Parkinson’s Disease to Neuroscience RoboticsOlaf Blanke, Geneva, CH

10:45-11:15 Coffee Break


Smarter DevicesChair: Kai Rösler, Bern and Basel, CH

11:15-11:45 Sensing and Computing Bits in Edge AI: Enabling Technologies for Future Human AvatarsAdrian Ionescu, Lausanne, CH

11:45-12:05 Virtual Reality Approaches to Study and Improve Cognitive and Motor Deficits after StrokeAndrea Serino, Lausanne, CH

12:05-12:30 Mobile Technologies for Remote, Patient Driven Neuro-Monitoring and StimulationWalter Karlen, Zurich, CH

12:30-13:15 Lunch

13:15-14:15 Garden 1BC

Satellite Symposium organized byWhen Progression Takes Over: Current and Emerging Treatment Options for SPMS PatientsChair: Ludwig Kappos, Basel, CH | Caroline Pot, Lausanne, CH

Welcome and IntroductionLudwig Kappos, Basel, CH | Caroline Pot, Lausanne, CH

Current Challenges in SPMS Diagnosis and TreatmentAndrew Chan, Bern, CH

Clinical Efficacy of Siponimod in SPMS PatientsTobias Derfuss, Basel, CH

Learnings from S1P-Modulator Experience: Initiation and MonitoringStefanie Müller, St. Gallen, CH

Panel DiscussionAndrew Chan, Bern | Tobias Derfuss, Basel | Ludwig Kappos, BaselStefanie Müller, St. Gallen | Caroline Pot, Lausanne, CH

Satellite Symposium

When progression takes over: Current and emerging treatment options for SPMS patients

Expect exciting talks on current challenges in SPMS and clinical

data. Panel discussion included. Also, visit us at Booth 20 for

topical news and short talks.

23th Oct 2019 | 1:15 – 2:15 p.m. | Plenary Room

NO

51974

Wednesday

17


13:15-14:15 Garden 2BC

Satellite Symposium organized by hATTR Amyloidosis – How to Navigate a Disease with Many FacesChair: Thierry Kuntzer, Lausanne, CH

Welcome and IntroductionThierry Kuntzer, Lausanne, CH

Overview and Experience with hATTR: Special Focus on PortugalAna Martins Silva, Porto, PT

Differential Diagnosis and Diagnostic Work-Up of hATTR NeuropathyHans Jung, Zurich, CH

Management of Patient Cases in LausanneMarie Théaudin, Lausanne, CH

13:15-14:00 Garden 3BC

Satellite Symposium organized by Radicava® in ALS: New PerspectivesChair: Olivier Scheidegger, Bern, CH

WelcomeOlivier Scheidegger, Bern, CH

Edaravone Trials in ALS: Study Design, Enrichment Strategy and EfficacyMarkus Weber, St. Gallen, CH

Practical Experience with Edaravone in ALSPaolo Ripellino, Lugano, CH



Acute-StrokeChairs: Marcel Arnold, Bern | Christoph Stippich, Zurich, CH

14:45-15:15 Endovascular Treatment of Acute Ischemic StrokeZsolt Kulcsàr, Zurich, CH

15:15-15:45 Treatment of Intracerebral Hemorrhage: Quo vadis?Urs Fischer, Bern, CH

Gemeinsame Jahrestagung 2020Schweizerische Kopfwehgesellschaft SKGSchweizerische Gesellschaft zum Studium des Schmerzes SGSS

Réunion Annuelle Commune 2020Société suisse pour l’étude des céphalées SSCSociété suisse pour l’étude de la douleur SSED

01.-02. Oktober 2020 | 01-02 octobre 2020BernExpo

First Announcement

Org

aniz

ed b

y IM

K In

stitu

te fo

r med

icin

e an

d co

mm

unic

atio

n Lt

d

© BERNEXPO GROUPE

YEARSSKG | SSC

IMSKKG2011 First Announcement_02.indd 1 28.08.19 12:18

Wednesday

19


14:45-15:45 Garden 1BC

Neuro-Intensive CareChairs: Karl Schaller, Geneva | Werner Z’Graggen, Bern, CH

14:45-15:05 Diagnosis of Cerebral VasospasmsWerner Z’Graggen, Bern, CH

15:05-15:25 Treatment of Symptomatic Cerebral Vasospasms: Established ConceptsEmanuela Keller, Zurich, CH

15:25-15:45 New Treatment Strategies for Cerebral VasospasmsJürgen Beck, Freiburg, DE

14:45-15:45 Garden 2BC

YouClin – Non-Epileptic Fit’s and Spells - a Multidisciplinary SessionChair: Alexandre Berney, Lausanne, CH

Participants: Indrit Bègue, Geneva, CHBigna Bölsterli, Zurich, CHMarkus Gschwind, Aarau, CH

14:45-15:45 Garden 3BC

Advances in Neurovascular Imaging and Impact on Clinical Decision MakingChairs: Michael Diepers, Aarau | Philippe Bijlenga, Geneva, CH

14:45-15:05 VWI – New Insights in Neurovascular DiseaseDavid M. Hasan, Iowa, USA

15:05-15:25 Imaging Assessment of Neurovascular LesionsMichael Diepers, Aarau, CH

15:25-15:45 Cerebrovascular Morphodynamics Analysis and Impact on Treatment PlanningPhilippe Bijlenga, Geneva, CH

14:45-15:45 Garden 4BC

Models of Human Memory – Part IChair: Radek Ptak, Geneva, CH

14:45-14:50 IntroductionRadek Ptak, Geneva, CH

14:50-15:15 Insights on Hippocampal Function from Developmental AmnesiaKlemens Gutbrod, Bern, CH

15:20-15:45 The Plasticity of Human Episodic Memory Radek Ptak, Geneva, CH


Mit wegweisenden Therapien komplexen Erkrankungen begegnen.

a gemessen in NNT (Number Needed to Treat)1 Freedman MS et al. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. Mult Scler Relat Disord 2016;10: 204–212. 2 Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 2017;12:59–63. 3 Comi G et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord 2016;5:97–104.Aubagio®. W: Teriflunomid. I: Schubförmig remittierende Multiple Sklerose (MS) bei Erwachsenen. D: 1 x täglich 14 mg . KI: Überemp-findlichkeit gegen den Wirkstoff oder einen der Hilfsstoffe; gleichzeitige Gabe mit Leflunomid, schwere Leberinsuffizienz oder Hypoprote-inämie, schwerer Immundefekt, schwere Knochenmarkinsuffizienz oder starke Anämie, Leukopenie, Neutropenie oder Thrombozytopenie, schwerer aktiver Infekt, Frauen im gebärfähigen Alter ohne zuverlässige Verhütung, Schwangerschaft; Stillzeit, < 18 Jahre und > 65 Jahre. Selten vererbte Galaktose-Intoleranz, Lapp Laktase-Mangel oder Glukose-Galaktose-Malabsorption VM: Bei Dialysepatienten Anwendung nicht empfohlen. Bei schwerwiegenden unerwünschten Wirkungen nach Abbruch der Therapie Auswaschmassnahmen in Betracht ziehen. Vor Beginn der Behandlung Untersuchung zur Früherkennung latenter Tuberkulose durchführen. Vor und während der Behandlung Blut-druck, Transaminasen, Bilirubin und grosses Blutbild inkl. Differentialblutbild überwachen. Anstieg der Leberwerte, insbesondere in den ersten 6 Monaten, beobachtet. Absetzen falls kein Rückgang auf normale Werte. Vorsicht bei starkem Alkoholkonsum. Bei Erhöhung des Blutdrucks Massnahmen ergreifen. Bei Auftreten von Symptomen für Leberschädigung, Infektionen, Lungenerkrankungen, hämatologische Erkrankungen, schwerwiegende Hautreaktionen, periphere Neuropathie, akute Niereninsuffizienz, Hyperkaliämie, interstitielle Pneumo-nie: unverzügliche diagnostische Abklärung erforderlich, ggf. Abbruch der Therapie und beschleunigte Eliminierung erwägen. Nicht bei schwerer Immundefizienz, Erkrankung des Knochenmarks oder schweren, unkontrollierten Infektionen empfohlen. Vor Behandlungsbeginn Früherkennung auf latente Tuberkulose durchführen. Auf adäquate Flüssigkeitszufuhr ist zu achten. Vorübergehendende Niereninsuffizienz bei gleichzeitiger Verabreichung von Urikosurika (Probenecid, Losartan). möglich. Bei Stomatitis ulcerosa absetzen. Vorsicht bei schwer-wiegenden Hautreaktionen: SJS, Lyell-Syndrom möglich. Bei gleichzeitiger Gabe von Warfarin engmaschige Kontrolle des INR empfohlen. Gabe von Lebendimpfstoffen vermeiden. Hämatologische Toxizität bei Umstellung auf anderen Wirkstoff überwachen. Zu Auswaschverfah-ren FI beachten. IA: Starke Induktoren von Cytochrom P450 und TransporternCYP1A2-Substrate; OAT3-Substrate; Rifampicin und andere CYP Induktoren und Transporter, Repaglinid; BCRP-Inhibitoren. Antibiotika bei Langzeitgabe Typ und Dosierung von eingenommenem Kontrazeptivum überdenken.. NW: Infektionen verschiedener Art, Neutropenie, Kopfschmerzen, GIT-Beschwerden, Alopezie, erhöhter Alanin-Aminotransferase-Wert. P: 28 oder 84 Filmtabl. à 14 mg AK: B*. Zul-Inh.: sanofi-aventis (schweiz) ag, 1214 Vernier/GE. Stand Info.: Mai 2017 (GZCH.AUBA.17.06.0071). Weitere Informationen entnehmen Sie bitte der Fachinformation unter www.swissmedicinfo.ch.G

ZCH

.AU

BA

.17.

11.0

155

Mehr Ruhe vor MS• Wirksamkeit: – Vergleichbare Reduktion der

Schubrate mit Dimethylfumarat und Fingolimoda,1

• Sicherheit: – Keine PML-Fälle2

– Keine erhöhte Malignität3

PGC_AUK_17005_Anzeige_UPDATE_DEU_148x210_RZ.indd 1 11.04.18 12:22

Wednesday

21



Baasch-Medicus-LectureChair: Christian W. Hess, Bern, CH

Nightly Use of Selective Histamine Antagonists as a Novel and Tailored Treatment Option in NarcolepsyPhilipp Valko, Zurich, CH

16:15-17:15 Garden 1BC

Intraoperative NeuromonitoringChairs: Karl Kothbauer, Lucerne, CH | Etienne Pralong, Lausanne, CH

16:15-16:30 Intraoperative SSEP-Monitoring in Neurosurgery: Still RelevantEtienne Pralong, Lausanne, CH

16:30-16:45 Intraoperative Mapping of the Motor Pathways in the Brain and Spinal CordKathleen Seidel, Bern, CH

16:45-17:00 Intraoperative Monitoring of Motor Evoked Potentials in Neurosurgery: More Relevant than EverKarl Kothbauer, Lucerne, CH

17:00-17:15 Intraoperative Assessment of the Visual Pathways in Neurosurgery: Finally Relevant?Colette Boex, Geneva, CH

16:15-17:15 Garden 2BC

YouCliN-AwardChairs: Claudio Bassetti, Bern, CH | Olivia Geisseler, Zurich, CH | Martin Stienen, Zurich, CH

16:15-16:25 P1 | Increased cortical beta oscillations prior to movement initiation in Parkinson’s disease patients with freezingF Brugger, J Walch, S Hägele-Link, S Bohlhalter, G Kägi | St. Gallen, CH; Luzern, CH; St. Gallen, CH

16:25-16:35 P2 | Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage and Mortality in Patients Taking DOAC vs VKA – Multicenter Registry, Systematic Review and Meta-AnalysisTR Meinel, D Seiffge, J Gralla, U Fischer, J Kaesmacher | Bern, CH

16:35-16:45 P3 | Development and external validation of a machine learning-based prediction model for functional impairment after intracranial tumor surgeryVE Staartjes, M Broggi, CM Zattra, F Vasella, J Velz, S Schiavolin, C Serra, J Bartek Jr, A Fletcher-Sandersjöö, P Förander, D Kalasauskas, M Renovanz, F Ringel, KR Brawanski, J Kerschbaumer, CF Freyschlag, AS Jakola, K Sjåvik, O Solheim, B Schatlo, A Sachkova, H Bock, A Hussein, V Rohde, ML Broekman, CO Nogarede, C Lemmens, J Kernbach, G Neuloh, O Bozinov, N Krayenbühl, J Sarnthein, P Ferroli, L Regli, MN Stienen | Zurich, CH; Milan, IT; Stockholm, SE; Mainz, DE; Innsbruck, AT; Gothenburg, SE; Tromsö, NO; Trondheim, NO; Göttingen, DE; Leiden, NL; Aachen, DE

®

A DACHSHUND ON A

MOTORBIKE TOUR

ONE OF THESE IS POSSIBLE WITH EMGALITY®

A MONTH OF MIGRAINE FREEDOM#

• Fast efficacy and high response rates2,3

› Significant reduction in migraine days from week 1 onwards4

› 3 in 5 patients achieved a ≥50% reduction in monthly migraine days

• Very good tolerability1

• Easy administration, once monthly§,1,5

The first antibody for migraine prophylaxis that binds to the CGRP neuropeptide1

NEWANDREIMBURSED

Emgality® (galcanezumab) solution for injection. I: Prophylactic treatment of migraine in adults, for whom prophylaxis is indicated. P: The recommended dose is 120 mg injected subcutaneously once monthly, with a 240 mg (2 injections) loading dose as the initial dose. CI: Hypersensitivity. W/P: If a serious hypersensitivity reaction occurs, administration of Emgality should be discontinued immediately and appropriate therapy initiated. The safety and efficacy of Emgality in children and adolescents have not been studied. Emgality can have an influence on the ability to drive and use machines. IA: No drug interaction studies were conducted. No pharmacokinetic drug interactions are expected based on the characteristics of galcanezumab. Pr/L: Emgality should not be used during pregnancy, unless it is clearly necessary. A decision should be made wether to stop breastfeeding or not to treat with Emgality. ADR: Very common: injection site reactions, injection site pain. Common: vertigo, constipation, pruritus. Cases of severe urticaria have been rarely reported. P: 1 and 2 prefilled pens of 120 mg, Dispensing category B. Consult www.swissmedicinfo.ch for further information. Eli Lilly (Suisse) SA, ch. des Coquelicots 16, CP 580, 1214 Vernier (GE). V03-2019

* For adults who have at least 4 migraine days per month. § The initial dose in the first month consists of 2 injections of 120 mg each. References: 1. Emgality® Professional information (www.swissmedicinfo.ch), Stand April 2019. 2. Stauffer VL et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9): 1080–1088. 3. Skljarevski V et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 4. Aurora SK, et al. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Post-hoc Analyses of Two Phase 3 Studies. J Headache Pain 2018, 19(Suppl 1):P132. Poster presented at the 12th European Headache Federation Congress. Florence, 20-30 September 2018. 5. Stauffer VL et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018;12:1785-1795. 6. Rosen N et al. 100 % Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results from Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies. Headache. 2018 Oct;58(9):1347-1357.

PP

-GZ

-CH

-00

13/0

4.2

019

# Nearly 40% of patients were migraine-free for at least one month 6

Wednesday

23

Garden 2BC YouCliN-Award (continued)

16:45:16:55 P4 | Damage of the lateral geniculate nucleus in MS: assessing the missing node of the visual pathwayA Papadopoulou, L Gaetano, A Pfister, A Altermatt, C Tsagkas, F Morency, AU Brandt, M Hardmeier, MM Chakravarty, M Descoteaux, L Kappos, T Sprenger, S Magon | Basel, CH; Sherbrooke, CA; Berlin, DE; Montreal, CA; Sherbrooke, CA; Wiesbaden, DE

16:55-17:05 P5 | Home-based sensor system for reliable motor-symptom monitoring in Parkinson’s disease patientsA Botros, P Urwyler, M Camenzind, D Bolliger, T Vanbellingen, R Kistler, S Bohlhalter, T Nef | Bern, CH; Luzern, CH

17:05-17:15 P6 | The Interleukin-6 receptor antagonist Tocilizumab reduces vasospasms, microclot formation and neuronal cell death in a rabbit model of subarachnoid haemorrhageD Croci, S Wanderer, B Grüter, S Sivanrupan, F Strange, M Von Gunten, L Andereggen, HR Widmer, S Di Santo, J Fandino, L Mariani, S Marbacher | Basel, CH; Aarau, CH; Bern, CH

16:15-17:15 Garden 3BC

Models of Human Memory – Part IIChair: Radek Ptak, Geneva, CH

16:15-16:40 Memory Systems Differ Regarding Processing ModeKatharina Henke, Bern, CH

16:40-17:15 Amnesia, Confabulation and the Construction of RealityArmin Schnider, Geneva, CH

16:15-16:45 Garden 4BC

Pitfalls of Misdiagnosis of DOCChairs: Thierry Ettlin, Rheinfelden, CH | Giulia Cossu, Lausanne, CH

Clinical Evaluation of Covert Consciousness to Avoid the Pitfalls of Misdiagnosis of DOCKarin Diserens, Lausanne, CH


General Assembly Swiss Neurological Society SNS (SNG)


Thur

sday

24

Daily overview Thursday | 24.10.2019

Auditorium C Garden 1BC Garden 2BC Garden 3BC Garden 4BC Garden 5BC08:15 - 08:30 08:15-09:30

Neuroimmunology and Neuroinflammation: Crosstalks

08:30 - 08:4508:45 - 09:0009:00 - 09:1509:15 - 09:3009:30 - 09:45 09:30-10:00 Coffee Break09:45 - 10:0010:00 - 10:15 10:00-11:15

Low back pain10:15 - 10:3010:30 - 10:45 10:30-12:30

SFND/ASDN Symposium10:45 - 11:0011:00 - 11:1511:15 - 11:3011:30 - 11:45 11:30-12:30

ePoster Session SNS

11:30-12:30ePoster Session SSNS|SSNR

11:30-12:30ePoster Session SLaE|SSCN

11:30-12:30ePoster Session SSBP|SSBN

11:30-12:30ePoster Session mix SSNP|SSNPath|SHSSSNRehab|SSS

11:45 - 12:0012:00 - 12:1512:15 - 12:3012:30 - 12:45

12:30-13:15 Lunch 12:30-13:15 Lunch 12:30-13:30 Lunch12:45 - 13:0013:00 - 13:1513:15 - 13:30 13:15-14:15

Satellite Symposium byRoche Pharma (Schweiz) AG

13:15-14:15Satellite Symposium byAlexion Pharma AG

13:15-14:15Satellite Symposium by Carl Zeiss AG & Neurochirurgie Kantonsspital Aarau AGIntraoperative Technology/ Imaging - Part I“

13:30 - 13:45 13:30-14:10SFND/ASDN Symposium

13:45 - 14:00

14:00 - 14:1512:30-13:30 Kaffeepause14:15 - 14:30

14:30 - 14:45 14:30-15:30Neuromuscular Session

14:30-15:30YouCliN- Neurotechnology: Challenges and Opportunities- a Multidisciplinary Session

14:30-15:30Intraoperative Technology/Imaging - Part II

14:30-15:30Urbanicity and Psychose14:45 - 15:00 14:40-15:40

SFND/ASDN Symposium15:00 - 15:1515:15 - 15:3015:30 - 15:45 15:30-16:00 Coffee Break 15:30-16:00 Coffee Break15:45 - 16:0016:00 - 16:15 16:00-17:00

Ultra high-field brain imaging16:00-17:00Swiss Narcolepsy Network (SNaNe)

16:00-17:00Spine surgery

16:00-17:00Primary Progressive Aphasia16:15 - 16:30

16:30 - 16:4516:45 - 17:0017:00 - 17:15 17:00-17:30 Coffee Break 17:00-17:30 Coffee Break17:15 - 17:3017:30 - 17:45 17:30-18:45

General Assembly SSCN(SGKN)

17:30-18:45General Assembly SSBP(SGBP)

17:30-18:45General Assembly SSNR(SGNR)

17:30-18:45General Assembly SSNS(SGNC)

17:30-18:45General Assembly SSBN(SGVN)

17:45 - 18:0018:00 - 18:1518:15 - 18:3018:30 - 18:4518:45 - 19:0019:00 - 19:15

as from 19:30 - Networking Event - Flying Dinner: Olympic Museum

Plenary Session SFND/ASDN Symposium

General Assembly (GA)

Parallel Session Satellite Symposium

ePoster

27

27

27

40

40 40 40

403939

38

37 37 38

31 3329

38 39

Thursday

25

Auditorium C Garden 1BC Garden 2BC Garden 3BC Garden 4BC Garden 5BC08:15 - 08:30 08:15-09:30

Neuroimmunology and Neuroinflammation: Crosstalks

08:30 - 08:4508:45 - 09:0009:00 - 09:1509:15 - 09:3009:30 - 09:45 09:30-10:00 Coffee Break09:45 - 10:0010:00 - 10:15 10:00-11:15

Low back pain10:15 - 10:3010:30 - 10:45 10:30-12:30


ePoster Session SNS





11:45 - 12:0012:00 - 12:1512:15 - 12:3012:30 - 12:45

12:30-13:15 Lunch 12:30-13:15 Lunch 12:30-13:30 Lunch12:45 - 13:0013:00 - 13:1513:15 - 13:30 13:15-14:15



13:15-14:15Satellite Symposium by Carl Zeiss AG & Neurochirurgie Kantonsspital Aarau AGIntraoperative Technology/ Imaging - Part I“

13:30 - 13:45 13:30-14:10SFND/ASDN Symposium

13:45 - 14:00

14:00 - 14:1512:30-13:30 Kaffeepause14:15 - 14:30

14:30 - 14:45 14:30-15:30Neuromuscular Session


14:30-15:30Intraoperative Technology/Imaging - Part II


SFND/ASDN Symposium15:00 - 15:1515:15 - 15:3015:30 - 15:45 15:30-16:00 Coffee Break 15:30-16:00 Coffee Break15:45 - 16:0016:00 - 16:15 16:00-17:00

Ultra high-field brain imaging16:00-17:00Swiss Narcolepsy Network (SNaNe)



16:30 - 16:4516:45 - 17:0017:00 - 17:15 17:00-17:30 Coffee Break 17:00-17:30 Coffee Break17:15 - 17:3017:30 - 17:45 17:30-18:45






17:45 - 18:0018:00 - 18:1518:15 - 18:3018:30 - 18:4518:45 - 19:0019:00 - 19:15


40

40

35

39

41

41

41

SFND/ASDN

Thursday

27

Program, Thursday | 24.10.2019


Neuroimmunology and Neuroinflammation: CrosstalksChairs: Krassen Nedeltchev, Aarau, CH | Kim Q. Do Cuénod, Lausanne, CH

08:15-08:40 Pediatric Inflammatory Brain Diseases – Overview and ManagementSandra Bigi, Bern, CH

08:40-09:05 The Innate/Adaptive Interface in CNS InflammationThorsten Buch, Zurich, CH

09:05-09:30 Neuroinflammation and Oxidative Stress in Schizophrenia Pathophysiology: a Translational ApproachKim Q. Do Cuénod, Lausanne, CH

09:30-10:00Coffee Break


Low Back PainChairs: Barbara Tettenborn, St. Gallen, CH | Javier Fandino, Aarau, CH

10:00-10:10 The Burden of Low Back PainJens Petersen, Zurich, CH

10:10-10:25 Added Value of Imaging in Acute Low Back PainJohan Van Goethem, Antwerpen, BE

10:25-10:50 Sense and Nonsense in Lumbar Spinal Stenosis Surgery Andreas Raabe, Bern, CH

10:50-11:15 Convincing Reasons for the Conservative ApproachSusanne Hartmann-Fussenegger, St.Gallen, CH


e-Poster Session SNSChair: Urs Fischer, Bern, CH

11:30-11:35 P7 | Detection of Intact Borrelia garinii in a sural nerve biopsyT Schneider, S Frank, B Tettenborn, F Fluri | St. Gallen, CH; Basel, CH

11:35-11:40 P8 | Disrupting myelin-specific Th17 cell trafficking to the gut dampens experimental autoimmune encephalomyelitisD Duc, S Vigne, J Bernier-Latmani, Y Yannick, F Ruiz, N Gaïa, L Stefano, V Lazarevic, J Schrenzel, T Petrova, C Pot | Lausanne, CH; Geneva, CH

11:40-11:45 P9 | Detection of novel CNS-specific antibodies using hiPSC-derived astrocytes and neurons: a pilot study on autoimmune-mediated neurological syndromesA Mathias, S Jones, S Perriot, N Torcida, M Théaudin, C Pot, R Du Pasquier | Lausanne, CH

Thur

sday

28


Auditorium C e-Poster Session SNS (continued)

11:45-11:50 P10 | Comparison of recent pivotal recommendations for the diagnosis and treatment of late onset Pompe disease using diagnostic nodesT Hundsberger, B Schoser, D Leupold, KM Rösler, PM Putora | St. Gallen, CH; München, DE; Melbourne, AU; Bern, CH

11:50-11:55 P11 | Small vessel disease is associated with an unfavorable outcome in stroke patients on oral anticoagulationL Hert, A Polymeris, S Schaedelin, J Lieb, D Seiffge, C Traenka, J Fladt, S Thilemann, H Gensicke, L Bonati, P Lyrer, S Engelter, N Peters | Basel, CH

11:55-12:00 P12 | Do we have the appropriate tools for measuring cognitive decline in PD-MCI patients?S Rosenblum, S Meyer, N Gemerman, L Mentzer, A Richardson, S Israeli-Korn, V Livneh, T Fay Karmon, T Nevo, G Yahalom, S Hassin-Baer | Haifa, IL; Ramat Gan, IL; Jerusalem, IL

12:00-12:05 P13 | Impact of dietary factors and circadian rhythms on Fatigue in multiple sclerosisG Thévoz, A Gauthier, SJ Eussen, T Collet, C Pot | Lausanne, CH; Maastricht, NL

12:05-12:10 P14 | Acute Ischemic Stroke, Atrial Fibrillation and Early DOAC-Treatment: 30-Day Risk of Recurrent Ischemic Stroke, Intracranial Haemorrhage in a Multi-Centre Individual Patient Data Meta-AnalysisGM De Marchis, DJ Seiffge, S Schädeline, D Wilson, V Caso, M Acciarresi, G Tsivgoulis, M Koga, S Yoshimura, K Toyoda, M Cappellari, B Bonetti, M Kosmas, B Kallmünzer, PA Lyrer, CW Cereda, M Paciaroni, ST Engelter, DJ Werring | Basel, CH; Bern, CH; London, GB; Perugia, IT; Athens, GR; Osaka, JP; Suita, JP; Verona, IT; Erlangen, DE; Lugano, CH

12:10-12:15 P15 | Tacrolimus in a patient with anti-HMGCR antibody-associated necrotizing autoimmune myopathyA Beuttler, S Hägele-Link, B Tettenborn, A Felbecker | St. Gallen, CH

12:15-12:20 P16 | 80Hz vs. 130Hz: Differential effect STN DBS frequency on Oculomotor vs. Stroop task performance: an exploratory, double blind studyA Zacharia, M Hariz, D Kaski | Geneva, CH; London, GB

12:20-12:25 P17 | First ever treatment in Multiple Sclerosis : Fingolimod vs dimethyl fuma-rate The Lausanne real life experienceV Pantazou, C Pot-Kreis, R Du Pasquier, M Théaudin | Lausanne, CH

12:25-12:30 P18 | Transcriptomic analysis of reactive human iPSC-derived astrocytes induced by neuroinflammatory cytokinesS Perriot, G Perriard, M Canales, A Mathias, R Pasquier | Epalinges, CH

Thursday

29


11:30-12:30 Garden 1BC

e-Poster Session SSNS | SSNRChairs: Isabel Wanke, Zurich, CH | Torstein Meling, Geneva, CH

11:35-11:40 P20 | Subdural versus subgaleal drainage for chronic subdural hematomas – a post hoc analysis of the TOSCAN trialS Vulcu, L Häni, M Branca, C Fung, WJ Z’Graggen, M Murek, A Raabe, J Beck, P Schucht | Bern, CH; Freiburg, DE

11:40-11:45 P21 | Pituitary function and endocrinological outcome of transsphenoidal surgery with respect to Shape-grade - a SwissPit studyC Grebhardt, P Schütz, J Fandino, S Berkmann | Aarau, CH

11:45-11:50 P22 | Current patterns of practice in spinal Fusion for chronic Low Back Pain – Results from a Survey at the German Spine Societies’ Annual Congress 2018D Baschera, L Westermann, S Syrianos, P Eysel, A Alfieri | Winterthur, CH; Cologne, DE

11:50-11:55 P23 | Reduction of external ventricular drain associated infections after intro-duction of a chlorhexidine containing dressingM Roethlisberger, S Stohler, DM Crovi, S Schön, S Leu, L Mariani | Basel, CH;Lugano, CH; Luzern, CH

11:55-12:00 P24 | Angiographic Analyses of natural anastomoses between the posterior and anterior cerebral arteries in Moyamoya diseaseS Bonasia, G Ciccio’, A Weil, S Smajda, C Chaalala, R Blanc, M Reinert, M PiotinM Bojanowski, T Robert | Lugano, CH; Paris, FR; Quebec, CA

12:00-12:05 P25 | Chemosensory function in posttraumatic patients: the role of olfactory distortionsAT May, J Hsieh, R Guatta, K Schaller, B Landis | Geneva, CH

12:05-12:10 P26 | Prehemorrhage antiplatelet use in aneurysmal subarachnoid haemorrhage and its impact on clinical outcomeM Sebök, E Keller, L Regli, B Coert, W Vandertop, A Sardeha, D Verbaan, MR Germans | Zurich, CH; Amsterdam, NL

12:10-12:15 P27 | Intravenous Thrombolysis versus Endovascular Therapy in Acute Middle Cerebral Artery M2-Segment Occlusion: A Monocenter Cohort StudyP Gruber, E Barvulsky, J Berberat, T Kahles, J Anon, M Diepers, K Nedeltchev, L Remonda | Aarau, CH

12:15-12:20 P28 | Build-Up Effect of Motor Evoked PotentialsN Frank, K Seidel, KF Kothbauer | Luzern, CH; Bern, CH

KEINE ZEIT FÜR KOPFSCHMERZEN

CHCH/CHPAN/0001/19 29.01.2019

GSK Consumer Healthcare Schweiz AGDies ist ein zugelassenes Arzneimittel. Lesen Sie die Packungsbeilage.

GSK Consumer Healthcare Schweiz AG unterstützt das Engagement der Schweizerischen Kopfwehgesellschaft gegen Kopfschmerzen.

Weitere Informationen zum Thema Kopfschmerz unter www.headache.ch

190502_PAN_Extra_Ins_148x210_d.indd 1 02.05.19 09:21

Thursday

31


Garden 1BC e-Poster Session SSNS | SSNR (continued)

12:20-12:25 P29 | Combating Glioblastoma: Activation of microglia by targeting CD47 and SiglecsP Schmassmann, T Shekarian, M Ritz, A Wachnowicz, T Martins, H Läubli, G Hutter | Basel, CH

12:25-12:30 P30 | Radiomics-based thrombus features predict the number of passes for arterial recanalization in patients with acute ischemic strokeJ Hofmeister, P Machi, G Bernava, A Rosi, S Burgermeister, MI Vargas, X Montet, K Lovblad | Genève, CH

11:30-12:30 Garden 2BC

e-Poster Session SLaE | SSCN

11:30-11:35 P31 | Brain functional connectivity predicts outcome in comatose patients after cardiac arrestT Kustermann, C Pfeiffer, NA Nguepnjo Nguissi, M Hänggi, R Zimmermann, F Zubler, M Oddo, A Rossetti, M De Lucia | Lausanne, CH; Zurich, CH; Bern, CH

11:35-11:40 P32 | MRI and EEG combination for outcome prediction in post-anoxic myoclonus, a retrospective multicentric studyI Beuchat, V Dunet, A Sivaraju, E Amorim, A Rossetti, JW Lee | Lausanne, CH; New Haven, US; Boston, US

11:40-11:45 P33 | A score to identify patients with good outcome after early epileptiform EEG following cardiac arrestG Barbella, JW Lee, V Alvarez, J Novy, M Oddo, AO Rossetti | Lausanne, CH; Boston, MA, US; Sion, CH

11:45-11:50 P34 | Correlation of somatosensory evoked potentials amplitude after cardiac arrest with other outcome prognosticatorsG Barbella, J Novy, M Oddo, AO Rossetti | Lausanne, CH; Monza, IT

11:50-11:55 P35 | High-density ECoG improves the detection of high frequency oscillations that predict seizure outcome.E Boran, G Ramantani, N Krayenbuhl, M Schreiber, K König, T Fedele, J Sarnthein | Zurich, CH; Moscow, RU

11:55-12:00 P36 | High-Frequency oscillations in scalp EEG mirror seizure frequency in pediatric focal epilepsyE Boran, J Sarnthein, N Krayenbuhl, G Ramantani, T Fedele | Zurich, CH; Moscow, RU

AXS Catalyst 5 Distal Access Catheter

AXS Infinity LS

Long Sheath

Excelsior XT-27 Microcatheter

Surpass Evolve Flow Diverter

Surpass Evolve™ Flow Diverter

Introducing

With the full access solution for your flow diversion needs.

Copyright © 2019 Stryker AP002561 v1.0

Thursday

33

AXS Catalyst 5 Distal Access Catheter

AXS Infinity LS

Long Sheath

Excelsior XT-27 Microcatheter

Surpass Evolve Flow Diverter

Surpass Evolve™ Flow Diverter

Introducing

With the full access solution for your flow diversion needs.

Copyright © 2019 Stryker AP002561 v1.0


Garden 2BC e-Poster Session SLaE | SSCN (continued)

12:00-12:05 P37 | Brain-computer interfaces based on cortical source activity during attempted movements reconstructed from high-density EEG in patients with amyotrophic lateral sclerosisC Pokorny, M Seeber, S Trznadel, T Proix, A Galvez, D D’Croz-Baron, A Yulzari, S Duboue, R Iancu Ferfoglia, A Kassouha, K Diserens, A Heritier Barras,J Janssens, U Chaudhary, N Birbaumer, C Michel, T Milekovic | Geneva, CH; Texas, US; Lausanne, CH; Tübingen, DE

12:05-12:10 P38 | Decoding gait events from high density EEG in healthy volunteers as preliminary step towards brain-controlled neuromodulation in people with paraplegia.A Galvez, M Sebeer, F Wagner, T Proix, LA McCracken, K Minassian, B Draganski, J Bloch, G Courtine, C Michel, T Milekovic | Lausanne, CH; Vienna, AT; Geneva, CH

12:10-12:15 P39 | Repetitive Ocular Vestibular Evoked Myogenic Potential (RoVEMP) Stimulation For Diagnosis of Myasthenia Gravis: Optimization Of Stimulation ParametersMA Wirth, Y Valko, SM Rosengren, T Schmückle-Meier, CJ Bockisch, D Straumann, K Landau, KP Weber | Zurich, CH; Sydney AU

12:15-12:20 P40 | Characteristics of acute MRI examinations in focal non-convulsive status epilepticus – a retrospective analysis.LL Imbach | Zurich, CH

12:20-12:25 P41 | Multi-modal intraoperative electrophysiological mapping of the anterior nucleus of the thalamus in refractory epilepsyLL Imbach | Zurich, CH

12:25-12:30 P42 | The Swiss Narcolepsy Scale (SNS) and its Short Form (sSNS) for the discrimination of narcolepsy in patients with hypersomnolence: A cohort study based on the Bern Sleep-Wake DatabaseA Dietmann, P Bargiotas, AG Haynes, M Garcia Calle, U Kallweit, MH Schmidt, J Mathis, C Bassetti | Bern, CH; Witten, DE

11:30-12:30 Garden 3BC

e-Poster Session SSBP | SSBNChairs: Thorsten Mikoteit, Solothurn, CH | Thierry Ettlin, Rheinfelden, CH

11:30-11:35 P43 | NAD+/NADH dysregulation revealed by 31P‐MRS in the Gclm KO mouse.R Skupienski, K Do Cuénod, L Xin | Lausanne, CH; Prilly, CH; Ecublens, CH

11:35-11:40 P44 | Mitochondrial dysfunction in Early Psychosis Patients: a translational studyI Khadimallah, M Fournier, J Cabungcal, M Cleusix, R Jenni, P Klauser, M Cuenod, P Conus, KQ Do | Prilly-Lausanne, CH

11:40-11:45 P45 | N-acetyl-cysteine treatment and environmental enrichment reversed the long-lasting effect of oxidative stress on PVI circuitry: relevance for schizophreniaD Dwir, J Cabungcal, P Steullet, M Cuénod, K Do Cuénod | Prilly, CH

C

M

Y

CM

MY

CY

CMY

K

Thursday

35

Garden 3BC e-Poster Session SSBP | SSBN (continued)

11:45-11:50 P46 | Correlation of microglial activation with white matter changes in dementia with Lewy bodiesN Nicastro, E Mak, G Williams, A Surendranathan, WR Bevan-Jones, L Pas-samonti, P Vazquez Rodriguez, L Su, R Arnold, F Aigbirhio, JB Rowe, JT O’Brien | Cambridge, GB

11:50-11:55 P47 | Slow wave promotes sleep-dependent plasticity during stroke recoveryL Facchin, C Schöne, A Mensen, M Bandarabadi, C Bassetti, AR Adamantidis | Bern, CH

11:55-12:00 P48 | Prediction of long-term outcomes in early psychosis: a new approach from topologyM Fournier, M Scolamiero, M Gholam-Reezaee, M Cleusix, R Jenni, P Golay, P Conus, K Hess, KQ Do | Prilly-Lausanne, CH

12:00-12:05 P49 | Amnestic syndrome in idiopathic Normal Pressure HydrocephalusA Lingenberg, F Herrmann, F Assal, G Allali | Geneva, CH

12:05-12:10 P50 | Systemic and CNS neuroinflammation is associated with neuropsychiatric symptomsC Clark, J Richiardi, G Bowman, J Popp | Thônex/Geneva, CH; Lausanne, CH; Boston, US

11:30-12:30 Garden 4BC

e-Poster Session mixSSNP, SSNPath, SHS, SSNRehab, SSSChair: Katrin Frauenknecht, Zurich, CH

11:30-11:35 P51 | ICH volume, haematoma expansion and 3-month-mortality in patients on antiplatelet therapy. A systematic review and meta-analysisM Goeldlin, U Fischer, D Seiffge | Bern, CH

11:35-11:40 P52 | Role of Caveolin-1 in neovascularization and astrogliosis after stroke and effects of cavtratin as a neuroprotectantC Blochet, L Buscemi, T Clément, J Badaut, L Hirt | Lausanne, CH; Bordeaux, FR, Loma Linda, US

11:40-11:45 P53 | Genetic findings in children with CNS arteriovenous fistulasG Saliou, A Vivanti, M Eyries, F Soubrier, J Melki, A Ozanne | Lausanne, CH; Bicetre, FR; Paris, FR

11:50-11:55 P55 | Flashing light therapy against photophobia in migraine – an fMRI studyTS Aslan | Wien, AT


SATELLITE SYMPOSIUM

LATEST CLINICAL DEVELOPMENTS IN NEUROSCIENCE

Chair

PD Dr. med. Marie Théaudin,

Senior Physician Clinic

for Neurology, University

Hospital Lausanne (CHUV)

Speaker

Prof. Dr. med. Andrew Chan,

Chief Physician Clinic for

Neurology and Head of the

University Outpatient Neuro-

centre, University Hospital

Bern (Inselspital)

Speaker

Prof. Dr. med. Sven Schippling,

Senior Physician Clinic for

Neurology, University Hospital

Zurich (USZ)

at the 4th congress of the Swiss Federation of Clinical

Neuro-Societies (SFCNS)

06/2

019

24TH OCT 2019 | 13:15 – 14:15SwissTech Convention Center Lausanne

OCR025 Kongress_Inserat_A5_E_2.indd 1 26.06.19 11:58

Thursday

37

Garden 3BC e-Poster Session mix (continued)

11:55-12:00 P56 | Rare genetic variants in patients with cervical artery dissectionC Traenka, M Kloss, T Strom, P Lyrer, T Brandt, L Bonati, C Grond-Ginsbach, S Engelter | Basel, CH; Heidelberg, DE; Munich, DE; Lucerne, CH

12:00-12:05 P57 | Enlarging the Transient Global Amnesia Spectrum: Vascular and other atypical triggers and manifestationsS Nannoni, S Piffer, V Beaud, O Rouaud, P Maeder, P Patrik | Lausanne, CH; Trento, IT

12:05-12:10 P58 | Serum neurofilament light chain predicts brain volume loss in patients with atrial fibrillationA Polymeris, T Sinnecker, P Benkert, N Rodondi, A Müller, J Beer, G Moschovitis, D Hayoz, J Novak, J Schläpfer, M di Valentino, U Fischer, A Monsch, J Wuerfel, M Schwenkglenks, M Kühne, S Osswald, D Conen, J Kuhle, L Bonati | Basel, CH; Zurich, CH; Baden, CH; Lugano, CH; Fribourg, CH; Solothurn, CH; Lausanne, CH; Bellinzona, CH; Bern, CH

12:10-12:15 P59 | Migraine and cervicogenic headache: analysis of pathogenic interactionOS Khayrutdinova, RA Giniatullin, EI Bogdanov | Kazan, RU; Kuopio, FI

12:15-12:20 P60 | Effect of a motor-cognitive dual-task training for MS-related fatigueF Estrada Daniele, D Pacifico, F Zucchetti, L Scarabel, P Rossi | Brissago, CH

12:20-12:25 P61 | Multimodal improvements after apomorphine treatment for chronic disorders of consciousness: preliminary resultsLRD Sanz, N Lejeune, EA Bonin, S Blandiaux, F Raimondo, R Panda, H Cassol, NM Farber, S Laureys, O Gosseries | Liège, BE; Waban, MA, US

12:25-12:30 P62 | Treatment of therapy refractory chronic cluster headache with the CGRP antibody erenumab – A case reportAL Keck, K Nedeltchev, L Achtnichts | Aarau, CH

12:30-13:15 Lunch

13:15-14:15 Garden 1BC

Satellite Symposium organized by Latest Cinical Developments in NeuroscienceChair: Marie Théaudin, Lausanne, CHSpeakers: Sven Schippling, Zurich, CH | Andrew Chan, Bern, CH

13:15-14:15 Garden 2BC

Satellite Symposium organized by New Horizons in Myasthenia Gravis – the New Therapeutic LandscapeChairs: Tobias Derfuss, Basel, CH | Hans Jung, Zurich, CH

The Neuromuscular Junction and the Role of Complement in Myasthenia GravisRuxandra Iancu Ferfoglia, Lausanne, CH

Novel Solutions for Refractory Myasthenia Gravis Management - from Clinical Trials to Clinical PracticeAngela Genge, Montreal, CA


Thur

sday

38

13:15-14:15 Garden 3BC

Satellite Symposium organized by Intraoperative Technology/Imaging - Part IChair: Javier Fandino, Aarau, CH

13:15-13:18 Introduction Javier Fandino, Klinik für Neurochirurgie, Kantonsspital Aarau, CH

13:19-13:34 Past, Present and Future of iMRI in Pituitary Surgery René Bernays, Klinik Hirslanden, Zurich, CH

13:35-13:50 Outcome Predictors after iMRI-guided Pituitary SurgerySven Berkmann, Klinik für Neurochirurgie, Kantonsspital Aarau, CH

13:51-14:06 Technical Developments in High-Frequency Intra-Operative Ultrasound-Guided SurgeryOliver Bozinov, Klinik für Neurochirurgie, Universitätsspital Zürich, CH

14:07-14:15 Discussion

14:30-15:30 Garden 1BC

Neuromuscular SessionChair: Thierry Kuntzer, Lausanne, CH

14:30-14:55 What’s new in peripheral neuropathies in complex inherited diseases?Thierry Kuntzer, Lausanne, CH

14:55-15:05 New treatment options for pediatric neuromuscular diseasesAndrea Klein, Basel, CH

15:05-15:30 Application of ultrasound for electrodiagnostic studiesOlivier Scheidegger, Bern, CH

14:30-15:30 Garden 2BC

YouCliN - Neurotechnology: Challenges and Opportunities- a Multidisciplinary SessionChairs: Adrian Guggisberg, Geneva, CH | Karin Bütler, Bern, CH

14:30-14:40 Artifical intelligence for image analysis in neuroradiologyRoland Wiest, Bern, CH

14:40-14:50 Concepts and clinical use cases for wearable devicesTobias Nef, Bern, CH

14:50-15:00 Virtual reality and serious games for cognitive neurorehabilitationArseny Sokolov, Lausanne, CH

15:00-15:30 Round TableChairs: Adrian Guggisberg, Geneva, CH | Karin Bütler, Bern, CH

Participants:Tobias Nef, Bern, CH | Arseny Sokolov, Lausanne, CH | Roland Wiest, Bern, CH


Thursday

39

14:30-15:30 Garden 3BC

Intraoperative Technology/Imaging - Part IIChair: Javier Fandino, Aarau, CH

14:31-14:46 Improved Quantative 5-ALA Visualization in Glioma and its Possible Implication for Surgical ResectionMichael Reinert, Lugano, CH

14:47-15:02 2D and 3D Intraoperative Angiography in Cerebrovascular Surgery Serge Marbacher, Aarau, CH

15:03-15:13 Key Remarks from Neuroradiological Point of ViewLuca Remonda, Aarau, CH

15:14-15:24 Key Remarks from Neurosurgical Point of ViewAndreas Raabe, Bern, CH

15:25-15:30 Discussion

14:30-15:30 Garden 4BC

Urbanicity and PsychosisChair: Sebastian Walther, Bern, CH

14:30-15:00 Brain Mechanisms of Environmental Risk for Psychiatric DisordersAndreas Meyer-Lindenberg, Mannheim, DE

15:00-15:30 Stress and the City : the Need for New Avenues to Explore the Link between Urbanicity and PsychosisPhilippe Conus, Lausanne, CH


16:00-17:00 Garden 1BC

Ultra High-Field Brain ImagingChair: Karl-Olof Lövblad, Geneva, CH

16:00-16:20 MRI Vessel Wall Imaging: Is it Time to Go Beyond the Degree of StenosisJavier M. Romero, Boston, US

16:20-16:40 Where Ultra High-Field Brain MRI Pays offPeter Jakob, Würzburg, DE

16:40-17:00 Epilepsy and UHF, New Contrasts and SemiologyMaria Isabel Vargas, Geneva, CH

16:00-17:00 Garden 2BC

Swiss Narcolepsy Network (SNaNe)Chair: Mehdi Tafti, Lausanne, CH

16:00-16:20 European and SNaNe DatabaseRamin Khatami, Barmelwaid, CH


Thur

sday

40


Swiss Narcolepsy Network (SNaNe) (continued)

16:20-16:40 The SPHYNCS StudyClaudio Bassetti, Bern, CH

16:40-17:00 Genetics of NarcolepsyMehdi Tafti, Lausanne, CH

16:00-17:00 Garden 3BC

Spine Surgery in Patients with Neurodegenerative DiseasesChair: Oliver Hausmann, Lucerne, CH

16:00-16:15 Camptocormia and Parkinson’s DiseaseDaniel Waldvogel, Lucerne, CH

16:15:16:45 Surgical Management of Spinal Deformities in Parkinson’s DiseaseYoon Ha, Seoul, South Korea

16:45-17:00 Imaging of the Degenerative SpineEberhard Kirsch, Basel, CH

16:00-17:00 Garden 4BC

Primary Progressive Aphasia: Clinical Presentations, Imaging & Language AnalysesChair: Hans-Albert Pihan, Biel, CH

16:00-16:20 Overview on PPAThomas Baumann, Bern, CH

16:20-16:50 Clinical Presentations, Imaging & Language AnalysesHans Pihan, Biel; Sandra Bucher, Biel, CH


General Assembly Neurophysiology SSNC (SGKN)

17:30-18:45 Garden 1BC

General Assembly Biological Psychiatry SSBP (SGBP)

17:30-18:45 Garden 2BC

General Assembly Neuroradiology SSNR (SGNR)

17:30-18:45 Garden 3BC

General Assembly Neurosurgery SSNS (SGNC)

17:30-18:45 Garden 4BC

General Assembly Behavioral Neurology SSBN (SGVN)

Thursday

41

SFND/ASDN | Thursday, 24.10.2019 | Garden 5BC

Chairs: Nicole Suter Jäggi, Wetzikon

10:30-11:10 Epilepsie im Alter – gar nicht so seltenStephan Rüegg, Basel, CH

11:10-11:50 Neue Gene bei kindlichen Epilepsien- Wie hilft uns dieses Wissen? Anja Leiber, St.Gallen, CH

11:50-12:30 Harte Schale, weicher Kern - eine Übersicht über die Anatomie des menschlichen Gehirns aus Sicht des ChirurgenLennart Henning Stieglitz, Zurich, CH

12:30-13:30 Lunch

13:30-14:10 Current use of evoked potentials: a review of different techniquesAgustina Lascano, Genf, CH

14:10-14:40 Kaffeepause

14:40-15:40 Fallstricke der EEG- und AnfallsanalyseJulia Bothmann, Zurich, CH

Frid

ay

42

Daily overview Friday | 25.10.2019

Auditorium C Garden 1BC Garden 4BC Garden 5BC Garden 3BC Garden 2BC08:00-08:30 Registration

08:30 - 08:45 08:30-09:45Dangerous Headache

08:30-08:45 Opening Symposium08:45 - 09:00 08:45-09:45

Session I | Multiple Sclerosis and Related Disorders

09:00 - 09:15 09:00-10:15IG-NOPPS09:15 - 09:30

09:30 - 09:4509:45 - 10:00 09:45-10:15 Coffee Break 09:45-10:45

Session II | Imaging of Sleep and Neurodegenerative Disorders

10:00 - 10:1510:15 - 10:30 10:15-11:15

Imaging findings in patients with headach

10:15-11:15YouCliN | Video Session

10:15-11:15Vertigo 10:15-10:45 Coffee break

10:30 - 10:4510:45 - 11:00 10:45-11:15 Coffee break 10:45-12:15

IG-NOPPS11:00 - 11:1511:15 - 11:30 11:15-12:00

Keynote Lecture I11:30 - 11:45 11:30-12:30Satellite Symposium byMerck (Schweiz) AG

11:30-12:30Satellite Symposium byEli Lilly (Suisse) SA

11:30-12:30Satellite Symposium byBioprojet

11:45 - 12:0012:00 - 12:15 12:00-13:00

Session III | Cutting Edge Neuromodulation

12:15 - 12:30

12:15-13:45 Lunch

12:30 - 12:45 12:30-13:00 Lunch12:45 - 13:0013:00 - 13:15 13:00-14:00

Headache for practitioners - case based

13:00-14:00Behavior Neurology

13:00-14:00Beyond clinical EEG in pre-surgical work-up: a glance upon neuronal networks

13:00-14:00 Lunch13:15 - 13:3013:30 - 13:4513:45 - 14:00 13:45-14:30

IG-NOPPS14:00 - 14:15 14:00-14:30 Coffee Break 14:00-15:00Session IV | Advanced Brain Tumor Imaging

14:15 - 14:3014:30 - 14:45 14:30-16:00

Brain of the future 14:30-15:00 Coffee break14:45 - 15:0015:00 - 15:15 15:00-16:00

Free communications I15:00-16:00IG-NOPPS15:15 - 15:30

15:30 - 15:4515:45 - 16:0016:00 - 16:15 16:00-16:30 Coffee break16:15 - 16:3016:30 - 16:45 16:30-17:30

Free communications II16:45 - 17:0017:00 - 17:1517:15 - 17:3017:30 - 17:45

17:30 Discussion and Closing Remarks

Plenary Session

5th OHBM Alpine Chapter


Parallel Session Satellite Symposium

IG-NOPPS

45

49

47 49 49

47 47 47

45 45 47

Friday

43

Auditorium C Garden 1BC Garden 4BC Garden 5BC Garden 3BC Garden 2BC08:00-08:30 Registration


08:30-08:45 Opening Symposium08:45 - 09:00 08:45-09:45

Session I | Multiple Sclerosis and Related Disorders

09:00 - 09:15 09:00-10:15IG-NOPPS09:15 - 09:30

09:30 - 09:4509:45 - 10:00 09:45-10:15 Coffee Break 09:45-10:45

Session II | Imaging of Sleep and Neurodegenerative Disorders

10:00 - 10:1510:15 - 10:30 10:15-11:15

Imaging findings in patients with headach


10:15-11:15Vertigo 10:15-10:45 Coffee break

10:30 - 10:4510:45 - 11:00 10:45-11:15 Coffee break 10:45-12:15

IG-NOPPS11:00 - 11:1511:15 - 11:30 11:15-12:00

Keynote Lecture I11:30 - 11:45 11:30-12:30Satellite Symposium byMerck (Schweiz) AG



11:45 - 12:0012:00 - 12:15 12:00-13:00


12:15 - 12:30

12:15-13:45 Lunch

12:30 - 12:45 12:30-13:00 Lunch12:45 - 13:0013:00 - 13:15 13:00-14:00

Headache for practitioners - case based



13:00-14:00 Lunch13:15 - 13:3013:30 - 13:4513:45 - 14:00 13:45-14:30

IG-NOPPS14:00 - 14:15 14:00-14:30 Coffee Break 14:00-15:00Session IV | Advanced Brain Tumor Imaging

14:15 - 14:3014:30 - 14:45 14:30-16:00

Brain of the future 14:30-15:00 Coffee break14:45 - 15:0015:00 - 15:15 15:00-16:00

Free communications I15:00-16:00IG-NOPPS15:15 - 15:30

15:30 - 15:4515:45 - 16:0016:00 - 16:15 16:00-16:30 Coffee break16:15 - 16:3016:30 - 16:45 16:30-17:30



5th OHBM Alpine Chapter IG-NOPPS

53

53

53

54

54

54

55

55

51

51

51

51

Wednesday | 23.10.2019

Daily overview Wednesday-Friday | 23.10.-25.10.2019

Auditorium C Garden 1BC Garden 2BC Garden 3BC Garden 4BC09:45 - 10:00 09:45-10:00 Opening10:00 - 10:15 10:00-10:45

Keynote Lecture10:15 - 10:3010:30 - 10:4510:45 - 11:00 10:45-11:15 Coffee Break11:00 - 11:1511:15 - 11:30 11:15-12:30

Smarter Devices11:30 - 11:4511:45 - 12:0012:00 - 12:1512:15 - 12:3012:30 - 12:45

12:30-13:15 Lunch12:45 - 13:0013:00 - 13:1513:15 - 13:30 13:15-14:15

Satellite SymposiumNovartis

13:15-14:15Satellite SymposiumAlnylam

13:15-14:00Satellite SymposiumMitsubishi Tanabe Pharma GmbH

13:30 - 13:45

13:45 - 14:00

14:00 - 14:1514:15 - 14:30 14:15-14:45 Coffee Break14:30 - 14:45

14:45 - 15:00 14:45-15:45Acute Stroke

14:45-15:45Neuro-Intensive Care

14:45-15:45YouCliN – a multidisciplinary session

14:45-15:45Advances in neurovascular imaging and impact on clinical decision making

14:45-15:45Models of human memory – Part I

15:00 - 15:1515:15 - 15:3015:30 - 15:4515:45 - 16:00 15:45-16:15 Coffee Break16:00 - 16:15

16:15 - 16:30 16:15-17:15Baasch-Medicus-Lecture

16:15-17:15Intraoperatives Neuromonitoring

16:15-17:15 YouCliN-Award

16:15-17:15Models of human memory – Part II

16:15-16:45Pitfalls of misdiagnosis of DOC16:30 - 16:45

16:45 - 17:0017:00 - 17:1517:15 - 17:3017:30 - 17:45 17:30-19:00

General Assembly SNS(SNG)

17:45 - 18:0018:00 - 18:1518:15 - 18:3018:30 - 18:4518:45 - 19:0019:00 - 19:15 from 19:30 Dinner Faculty/Speakers

Plenary Session


Parallel Session

Satellite Symposium

15

15

15 17 17

17 19 19 19 19

1923232121

23

Thursday | 24.10.2019Auditorium C Garden 1BC Garden 2BC Garden 3BC Garden 4BC Garden 5BC

08:15 - 08:30 08:15-09:30Neuroimmunology and Neuroinflammation: Crosstalks

08:30 - 08:4508:45 - 09:0009:00 - 09:1509:15 - 09:3009:30 - 09:45

09:30-10:00 Coffee Break09:45 - 10:0010:00 - 10:15 10:00-11:15

Low back pain10:15 - 10:3010:30 - 10:45 10:30-12:30


ePoster Session SNS





11:45 - 12:0012:00 - 12:1512:15 - 12:3012:30 - 12:45

12:30-13:15 Lunch 12:30-13:30 Lunch12:45 - 13:0013:00 - 13:1513:15 - 13:30 13:15-14:15



13:15-14:15Satellite Symposium by Carl Zeiss AG & Neurochirurgie Kantonsspital Aarau AG

13:30 - 13:45 13:30-14:10SFND/ASDN Symposium13:45 - 14:00

14:00 - 14:1514:15 - 14:30

14:10-14:40 Kaffeepause14:30 - 14:45 14:30-15:30Neuromuscular Session


14:30-15:30Intraoperative Technologie/Imaging - Part II


SFND/ASDN Symposium15:00 - 15:15

15:15 - 15:30

15:30 - 15:4515:30-16:00 Coffee Break15:45 - 16:00

16:00 - 16:15 16:00-17:00Ultra high-field brain imaging

16:00-17:00Swiss Narcolepsy Network (SNaNe)



16:30 - 16:4516:45 - 17:0017:00 - 17:15

17:00-17:30 Coffee Break17:15 - 17:3017:30 - 17:45 17:30-18:45






17:45 - 18:0018:00 - 18:1518:15 - 18:3018:30 - 18:4519:00 - 19:15


Plenary Session

SFND/ASDN Symposium



Parallel Session

Satellite Symposium

ePoster

27

27

27

40 40 40 40 40

40 403939

38

37 37 38

31 33 3529

38 39 39

41

41

41

Friday | 25.10.2019Auditorium C Garden 1BC Garden 4BC Garden 5BC Garden 3BC Garden 2BC Garden 3A

08:00-08:30 Registration


08:30-08:45 Opening Symposium

08:45 - 09:00 08:45-09:45Session I | Multiple Sclerosis and Related Disorders

09:00 - 09:15 09:00-10:15IG-NOPPS09:15 - 09:30

09:30 - 09:4509:45 - 10:00

09:45-10:15 Coffee Break 09:45-10:45Session II | Imaging of Sleep and Neurodegenerative Disorders

10:00 - 10:1510:15 - 10:30 10:15-11:15

Imaging findings in patients with headache


10:15-11:15Vertigo

10:15-10:45 Kaffeepause10:30 - 10:4510:45 - 11:00

10:45-11:15 Coffee break 10:45-12:15IG-NOPPS11:00 - 11:15

11:15 - 11:30 11:15-12:00Keynote Lecture I11:30 - 11:45 11:30-12:30

Satellite Symposium byMerck (Schweiz) AG



11:45 - 12:0012:00 - 12:15 12:00-13:00


12:15 - 12:30

12:15-13:45 Lunch

12:30 - 12:4512:30-13:00 Lunch12:45 - 13:00

13:00 - 13:15 13:00-14:00Headache for practitioners - case based



13:00-14:00 Lunch13:15 - 13:3013:30 - 13:4513:45 - 14:00 13:45-14:30

IG-NOPPS14:00 - 14:1514:00-14:30 Coffee Break 14:00-15:00

Session IV | Advanced Brain Tumor Imaging

14:15 - 14:3014:30 - 14:45 14:30-16:00

Brain of the future14:30-15:00 Kaffeepause 14:30-15:30

General Assembly SHS(SKG)

14:45 - 15:0015:00 - 15:15 15:00-16:00

Free communications I15:00-16:00Generalsversammlung IG-NOPPS

15:15 - 15:3015:30 - 15:4515:45 - 16:0016:00 - 16:15

16:00-16:30 Coffee break16:15 - 16:3016:30 - 16:45 16:30-17:30





IG-NOPPS

IG-NOPPS

SFND/ASDN

45

49

47 49 49

47 47 47

45 45 47

53

53

53

54

54

54

54

55

55

51

51

51

51Plenary Session

Parallel Session

Satellite Symposium

49

IMNFKG19 Tagesuebersicht_Mi-Fr_hoch_A0_01.indd 1 11.10.19 13:20

First Announcement

Org

aniz

ed b

y IM

K In

stitu

t für

Med

izin

und

Kom

mun

ikat

ion

AG

Jahrestagung 2020Schweizerische Neurologische Gesellschaft

Gastgesellschaft:Schweizerische Gesellschaft für Verhaltensneurologie

Réunion annuelle 2020Société Suisse de Neurologie

Société Invitée:Société Suisse de Neurologie Compartementale

19.-20. November 2020Congress Centre Kursaal Interlaken

IMSNKG2011_First_Announcement_03.indd 1 26.08.19 10:00

Friday

45

Program, Friday | 25.10.2019


Dangerous HeadacheChairs: Andreas Raabe, Bern, CH | Christoph Stippich, Zurich, CH

08:30-08:55 Dangerous Headaches: Not Always HemorrhagesAndreas Straube, Munich, DE

08:55-09:20 Specific Imaging Strategies and Findings in Patients with HeadachesOlav Jansen, Kiel, DE

09:20-09:45 Special aspects: CSF and Vascular CausesJürgen Beck, Freiburg, DE

09:45-10:15 Coffee break

10:15-11:15 Garden 1BC

Imaging Findings in Patients with HeadacheChair: Roland Wiest, Bern, CH

10:15-10:35 Neuroimaging of Spinal Causes of HeadacheMaria Isabel Vargas, Geneva, CH

10:35-10:55 Update on Brain Imaging in Migraine and Cluster HeadacheLars Michels, Zurich, CH

10:55-11:15 No Brainers: Dural and Extradural Pathologies - a Pictorial EssayFranca Wagner, Bern, CH

10:15-11:15 Garden 4BC

YouCliN – Video SessionChairs: Bigna Bölsterli, Zurich, CH | Rebekka Zimmermann, Bern, CH |Samuel Sommaruga, Geneva, CH

10:15-10:30 V1 | Case series of diastematomyelia, technical reportR Guatta, AT May, A Bartoli, K Schaller | Genève, CH

10:30-10:45 V2 | Differential diagnosis of myotonia: Is temperature the key?H Hammer, C Maurer, N Kamber, A Dietmann, O Scheidegger | Bern, CH

10:45-11:00 V3 | Fluorescence Angiography for Evaluation of Aneurysm Perfusion and Parent Artery Patency in a Rat and Rabbit Aneurysm ModelF Strange, BE Gruter, S Sivanrupan, J Rey, D Taeschler, D Coluccia, J Fandino, S Marbacher | Aarau, CH; Bern, CH

11:00-11:15 V4 | Episodic axial muscle hyperextension as an early presentation of an epileptic encephalopathyR Eberhard, R Steinfeld | Zurich, CH

First Announcement

Org

aniz

ed b

y IM

K In

stitu

t für

Med

izin

und

Kom

mun

ikat

ion

AG

Jahrestagung 2020Schweizerische Neurologische Gesellschaft

Gastgesellschaft:Schweizerische Gesellschaft für Verhaltensneurologie

Réunion annuelle 2020Société Suisse de Neurologie

Société Invitée:Société Suisse de Neurologie Compartementale

19.-20. November 2020Congress Centre Kursaal Interlaken

IMSNKG2011_First_Announcement_03.indd 1 26.08.19 10:00

Frid

ay

46

Satellite symposium 4th SFCNS Congress, Lausanne

11:30 – 12:30 Friday, 25.10.2019Garden 1BC

MAVENCLAD® – THE NEW ORAL TREATMENT FOR MULTIPLE SCLEROSIS

CH

/CLA

/061

9/0

080

(1)

ChairsProf. Dr. med. Andrew Chan Inselspital, Universitätsspital Bern

Prof. Dr. med. Caroline Pot CHUV, Lausanne

SpeakersProf. Dr. med. Tobias Derfuss Universitätsspital Basel

Prof. Dr. med. Sven Schippling Universitätsspital Zürich

Dr. med. Klaus Schmierer Queen Mary University of London/ Barts Health NHS Trust

Merck (Schweiz) AG | Chamerstrasse 174 | 6300 Zug

MAVENCLAD® (10 mg de cladribine). I: Patients adultes atteints de sclérose en plaques (SEP) récurrente-rémittente très active, définie par des constats cliniques ou d‘imagerie médicale. PO: Dose de 3,5 mg/kg de poids corporel, répartie sur 2 ans sous forme d‘un cycle de traitement de 1,75 mg/kg par an. CI: Hypersensibilité à la cladribine ou à l‘un des excipients. Infection par le virus de l‘immunodéficience humaine (VIH). Infection sévère active, infection chronique active (p.ex. tuberculose ou hépatite). Instauration du traitement chez les patients immunodéprimés. Présence d‘un cancer actif. Antécédent de leucoencéphalopathie multifocale progressive. Insuffisance rénale modérée ou sévère. Enfants et adolescents de moins de 18 ans. Grossesse et allaitement. PR: De façon générale: non recommandé chez les patients dont la maladie est inactive ou stabilisée sous un traitement établi. Ne pas administrer plus de 2 cycles de traitement annuels en 4 ans. Surveillance hématologique: le taux de lymphocytes doit être vérifié avant le début du traitement par Mavenclad les années 1 et 2 ainsi que 2 et 6 mois après le début de chaque cycle de traitement administré. Infections: La cladribine peut affaiblir les défenses immunitaires du patient et éventuellement accroître le risque d‘infections. Les patients dont le taux de lymphocytes est inférieur à 500 cellules/mm3 doivent être surveillés activement quant aux signes et symptômes d‘infections, en particulier du zona. Cancers: La cladribine interfère avec la synthèse d‘ADN et a un effet immunosuppresseur. Contraception: Des méthodes fiables de contraception doivent être utilisées pendant le traitement par la cladribine et encore au moins 6 mois après la dernière dose. Transfusions sanguines: chez les patients devant recevoir des transfusions sanguines, il est recommandé d‘irradier les produits sanguins avant la transfusion. Passage d’un autre traitement à cladribine et inversement: le mécanisme d‘action et la durée d‘action de l‘autre médicament doivent être pris en compte avant le début du traitement par Mavenclad. Affections rénales: Mavenclad ne doit pas être utilisé chez les patients présentant une insuffisance rénale modérée ou sévère. Affections hépatiques: Mavenclad n‘est pas recommandé chez les patients présentant une insuffisance hépatique modérée ou sévère. Intolérance au fructose: les patients présentant une intolérance au fructose ne doivent pas prendre Mavenclad. IA: Mavenclad contient de l’hydroxypropylbétadex qui peut éventuellement former des complexes avec d‘autres médicaments et accroître ainsi leur biodisponibilité. Médicaments hématotoxiques ou immunosuppresseurs (méthotrexate, cyclophosphamide, ciclosporine, azathioprine, corticostéroïdes). Autres agents modificateurs de la

maladie. Médicaments hématotoxiques (carbamazépine). Vaccins vivants ou vivants atténués. Inhibiteurs puissants des transporteurs ENT1, CNT3 et BCRP (p. ex. dilazep, nifédipine, nimodipine, cilostazol, sulindac, réserpine). Inducteurs puissants des transporteurs BCRP et P-gp (p.ex. corticostéroïdes, rifampicine, millepertuis). Contraceptifs hormonaux. EI les plus fréquents: lymphopénie, herpès buccal, zona touchant un dermatome, taux réduit de neutrophiles, éruption cutanée, alopécie. P: Mavenclad 10 mg: 1, 4 ou 6 comprimés. [A] Pour des informations plus détaillées, veuillez consulter www.swissmedicinfo.ch. AVR19

Friday

47


10:15-11:15 Garden 5BC

VertigoChair: Dominik Straumann, Zurich, CH

10:15-10:35 Differential Diagnosis of Acute VertigoGeorgios Mantokoudis, Bern, CH

10:35-10:55 Central Vertigo SyndromesAlexander A. Tarnutzer, Baden, CH

10:55-11:15 Positional VertigoDominik Straumann, Zurich, CH

11:30-12:30 Garden 1BC

Satellite Symposium organized by MAVENCLAD® – The New Oral Treatment for Multiple SclerosisChairs: Andrew Chan, Bern, CH | Caroline Pot, Lausanne, CHSpeakers: Tobias Derfuss, Basel, CH; Klaus Schmierer, London, UK

11:30-12:30 Garden 4BC

Satellite Symposium organized by New Treatment Options in Migraine and Their Impact on Quality of LifeChair: Reto Agosti, Zollikon, CHSpeakers: Andreas Gantenbein, Bad Zurzach, CH; Christoph Schankin, Bern, CH

11:30-12:30 Garden 5BC

Satellite Symposium organized by Wakix: a New Cerebral H3 Receptor Inverse Agonist. Impact in Narcolepsy ManagementChair: Claudio Bassetti, Bern, CH

Narcolepsy: Update on PhysiopathologyClaudio Bassetti, Bern, CH

Pitolisant Clinical Data and Lausanne Experience (Compassionate Use program)José Haba-Rubio, Lausanne, CH

Pitolisant Mechanism of Action, its Use and Multiple Treatment Comparison AnalysisChristian Caussé, Paris, FR

12:30-13:00 Lunch

13:00-14:00 Garden 1BC

Headache for Practitioners – Case BasedChairs: Peter Sandor, Bad Zurzach, CH | Christoph Schankin, Bern, CH

13:00-13:20 State-of-the-Art Migraine Therapy in Cooperation between Primary Care Physicians and NeurologistsSilke Biethahn, Aarau, CH

13:20-13:40 Headache Treatment - Tricky CasesAndreas Gantenbein, Bad Zurzach, CH

13:40-14:00 When to Send Headache Patients to the Emergency Room?Andreas Kleinschmidt, Geneva, CH

ORIGINALSCHWEIZER GENERIKA. SEIT 1886.

Vertrauen auch Sie unserer über 130-jährigenExpertise, wenn Sie Ihren nächsten Patientenmit psychiatrischen und neurologischenErkrankungen behandeln.

CH

1902

9691

40 0

3/20

19

Sandoz Pharmaceuticals AG, Suurstoffi 14, 6343 Rotkreuz I www.sandoz-pharmaceuticals.ch

VERTRAUEN VERBINDET. VERTRAUEN VERPFLICHTET.

11093115 CNS Ad_SP v1c.indd 2 01/05/2019 16:29

Friday

49


13:00-14:00 Garden 4BC

Behavior NeurologyChair: Thierry Ettlin, Rheinfelden, CH

13:00-13:20 Transcranial Magnetic Stimulation (TMS) in Neglect RehabilitationThomas Nyffeler, Lucerne, CH

13:20-13:40 EEG and Neurofeedback of NeglectPatrik Vuilleumier, Geneva, CH

13:40-14:00 Non-Invasive Brain Stimulation to Enhance Motor and Visual Functions after Brain LesionsFriedhelm Christoph Hummel, Geneva, CH

13:00-14:00 Garden 5BC

Beyond Clinical EEG in Pre-Surgical Work-Up: a Glance Upon Neuronal NetworksChair: Jan Novy, Lausanne, CH

13:00-13:30 Hyperdimensional iEEG analysisKaspar Schindler, Bern, CH

13:30-14:00 What Microelectrode Recordings Can Tell Us About Epilepsy and its NetworkPierre Mégevand, Geneva, CH


14:30-15:30 Garden 3A

General Assembly Swiss Headache Society SHS (SKG)


Brain of the FutureChairs: Karl-Olof Lövblad, Geneva, CH; Andrea Rossetti, Lausanne, CH

14:30-14:40 Antonios Valavanis Honorary MedalRecipient of the Honorary Medal: Luc Picard, Nancy, FRLaudation by: Karl-Olof Lövblad, Geneva, CH

14:40-15:00 Neurology: “Eppur si muove” From a diagnostic to a therapeutic specialtyClaudio Bassetti, Bern, CH

15:00-15:20 The prevention of stroke and Alzheimer’s disease: the old and the newGiovanni Frisoni, Geneva, CH

15:20-15:40 Advances and Perspectives on the treatment of neurovascular diseasesVitor Mendes Pereira, Toronto, USA

15:40-16:00 Neuroprosthetic technologies for restoring leg motor control after paralysisJocelyne Bloch, Lausanne, CH

Welcomes All Attendees to4th SFCNS Congress

A 360-Degree Approach to Neuroendovascular Therapy

MICROVENTION, SOFIA and HYDROCOIL are registered trademark of MicroVention, Inc. and WEB is a trademark of Sequent Medical, Inc. • Refer to Instructions for Use, contraindications and warnings for additional information. © 2019 MicroVention, Inc. 6/19.

WEB SL® & WEB® SLSAneurysm Embolization System

SOFIA® Aspiration Catheters

Hydrogel CoilsHydroCoil® Embolic System

Friday

51

IG-NOPPS | Friday, 25.10.2019 | Garden 2BC

Chair: Jürgen Schmidt, Biel, CH

09:00-09:15 BegrüssungJürgen Schmidt, Basel, CH

09:15-09:45 Nervenwachstum, Nervenzüchtung: Was tut sich in der Forschung? Raphael Guzman, Basel, CH

09:45-10:15 Nachbetreuung neurochirurgischer Patienten auf IMC und Indikationen zur OP Werner Z’Graggen, Bern, CH

10:15-10:45 Kaffeepause

10:45-11:15 Hirnstammimplantate ForschungLennart Henning Stieglitz, Zürich, CH

11:15-11:45 Lasertechnik im OP Einsatz bei Tumorbehandlung im GehirnStefanie Ruh, Zürich, CH

11:45-12:15 Sicherheitsrelevante Massnahmen in KrisensituationenIstvan Stanko, Basel, CH

12:15-13:45 Lunch

13:45-14:30 Funktionsüberwachung des motorischen Systems bei Neurochirurgischen Eingriffen - Wie schützen wir Patienten bei Hoch-Risiko Operationen?Kathleen Seidel, Bern, CH

14:30-15:00 Kaffepause

15:00-16:00 Generalversammlung IG–NOPPS

06/2

019_

0151

_I&I

INVITATIONSATELLITE SYMPOSIUM BY CELGENE

Measuring grey matterand thalamic volume loss and their clinical relevance in MS treatment

SFCNS Imaging Course 2019Saturday, October 26, 201913.15–14.00Hotel Mövenpick, Lausanne

SpeakerProf. Dr. med. Sven SchipplingUniversitätsSpital Zürich

In Multiple Sclerosis-

GREY MATTERS, TOO Think White and Grey to Complete the Picture

Celgene GmbH | Bändliweg 20 | 8048 Zürich | [email protected] | www.celgene.ch | T +41 44 437 88 00 | F +41 44 437 88 88

Friday

53

5th OHBM Alpine Chapter Symposium | Friday, 25.10.2019 | Room Garden 3BC

08:00-08:30 Registration

08:30-08:45 Opening SymposiumChristoph Stippich, Zurich, CH

08:45-09:45 Session I | Multiple Sclerosis and Related DisordersChair: Christian Enzinger, Graz, AT

08:45-09:05 New Avenues to Functional Connectivity AnalysesMenno Schoonheim, Amsterdam, NL

09:05-09:25 Improvements in Assessing Gray and White Matter Volume Changes on Brain MRIMarco Battaglini, Siena, IT

09:25-09:45 Fully Automated Grey and White Matter Spinal Cord Segmentation in MSFerran Prados Carrasco, London, UK

09:45-10:45 Session II | Imaging of Sleep and Neurodegenerative DisordersChairs: Elke Gizewski, Innsbruck, AT | Roland Wiest, Bern, CH

09:45-10:00 Morphometry of Movement DisordersChristian Rummel, Bern, CH

10:00-10:15 Imaging in neurological sleep disordersEvi Holzknecht, Innsbruck, AT

10:15-10:30 Advances of UHF in Neurodegenerative DisordersElke Gizewski, Innsbruck, AT

10:30-10:45 Parkinson’s Disease and Rem-Sleep DisordersPanagiotis Bargiotas, Bern, CH

10:45-11:15Coffee break

11:15-12:00 Keynote Lecture IClinical Effects of Current Electrophysiological Brain StimulationMark Hallett, Washington, US

Frid

ay

54

12:00-13:00 Session III | Cutting Edge NeuromodulationChairs: Roland Beisteiner, Vienna, AT | Mark Hallett, Washington, US

12:00-12:30 Ablation and Blood Brain Barrier Therapy with Focused UltrasoundAndres Lozano, Toronto, CA

12:30-12:45 Non-Lesional Neuromodulation with UltrasoundRoland Beisteiner, Vienna, AT

12:45-13:00 Focused Ultrasound Neuromodulation in Acute and Chronic Disorders of ConsciousnessMartin M. Monti, Los Angeles, US

13:00-14:00Lunch

14:00-15:00 Session IV | Advanced Brain Tumor ImagingChair: Christoph Stippich, Zurich, CH

14:00-14:20 Multimodal Imaging and Advanced Image Analysis of GliomasBenedikt Wiestler, Munich, DE

14:20-14:40 Application of Deep Learning and Radiomics in Brain Tumor ImagingPhilipp Kickingereder, Heidelberg, DE

14:40-15:00 Brain Tumor Metabolism in MR-SpectroscopyElke Hattingen, Frankfurt, DE

15:00-16:00 Free communications IChair: Elke Gizewski, Innsbruck, AT

15:00-15:10 Effects of Transcranial Pulse Stimulation with Ultrasound (Tps) on Somatosensory Evoked Potentials in HumansEva Matt, Vienna, AT

15:10-15:20 fMRI in Patients? Vascular Pathophysiological Effects Exampled on a Human Translational ModelMarco Piccirelli, Zurich, CH

15:20-15:30 Fast and Direct Estimation of Human Brain Morphometry via Deep LearningMichael Rebsamen, Bern, CH

15:30-15:40 Deep Learning Based Detection and Localization of Intracranial Aneurysms in Digital Subtraction AngiographyManoj Mannil, Zurich, CH


Friday

55

sponsored by

15:40-15:50 Hippocampal Subfields and PsychiatryRené Seiger, Vienna, AT

15:50-16:00 Microstructure of the Thalamus in Early Psychosis and Chronic Patients Based on Diffusion Weighted Magnetic Resonance ImagingYasser Alemán-Gómez, Lausanne, CH

16:00-16:30Coffee break

16:30-17:30 Free communications IIChair: Anja Ischebek, Graz, AT

16:30-16:40 Age- and Gender Effects on Brainstem MR-PlanimetryStephanie Mangesius, Innsbruck, AT

16:40-16:50 Graph-Based Analysis of the Change of the Resting State Connectivity Networks Under the Open Monitoring MeditationSergiy Pereverzyev Jr., Innsbruck, AT

16:50-17:00 Flexible Use of Emotional Resources in Resilient Emerging Adults – An fMRI StudyChristian Siedentopf, Innsbruck, AT

17:00-17:10 The Influence of Daily Caffeine Consumption on Human Brain Morphometry and CognitionYu-Shiuan Lin, Basel, CH

17:10-17:20 Supra- and Infratentorial Atrophy Following Clinically Isolated Syndromes: a 30-Year Follow-Up StudyLukas Haider, London, UK

17:20-17:30 Neuropsychological Profile in a Patient with Coffin-Siris-Syndrom: a Case ReportNina Bechtel, Basel, CH

17:30 Discussion and Closing RemarksChristoph Stippich and all chairs


Grünenthal Pharma AG, 8756 Mitlödi

Gekürzte Fachinformation Zomig® nasal: C: Zolmitriptanum; Zomig® Filmtabl. zu 2,5 mg resp. Zomig® oro Lingualtabl. zu 2,5 mg resp. Zomig® nasal Nasalspray zu 2,5 mg oder 5 mg; Liste B. I: akute Migräne anfälle, Cluster-Kopfschmerz (nur Zomig® nasal). D: Migräne: 1x 2,5 mg (Zomig®, Zomig® oro oder Zomig® nasal) oder 1x 5 mg (Zomig® nasal); max. 10 mg/24 h. Cluster-Kopfschmerz: 1x 5 mg oder 10 mg Zomig® nasal. KI: Überempfindlichkeit, ischämische Herzerkrankungen, Myokardinfarkt in Vorgeschichte, koronare Vasospasmen (Prinzmetal-Angina), unzureichend eingestellte Hypertonie. V: Epilepsie, strukturelle Hirnschädigungen, Herzkrankheiten, Therapie mit Ergotaminen oder SSRI’s, Dosisreduktion bei gleichzeitiger Verabreichung von MAO-A-Hemmern, Phenylketonurie (Zomig® oro), Schwangerschaft. INT: Cimetidin, CYP1A2- Inhibitoren. UAW: sehr häufig: Geschmackstörungen (nur Zomig® nasal). Häufig: Schwindel, Kopfschmerzen, Schläfrigkeit, Wärmegefühl, Parästhesie und Hyperästhesie, Herzklopfen, Nasenbluten (nur Zomig® nasal), unangenehmes Gefühl in der Nasenhöhle (nur Zomig® nasal), Bauchschmerzen, Nausea, Erbrechen, Mundtrockenheit, Dysphagie, Muskelschwäche, Myalgie, Asthenie, Schwere-, Enge-, Schmerz- oder Druckgefühl in Hals, Nacken, Kiefer, Extremitäten und Thorax. Kassenzulässig. Liste B. Ausführliche Angaben siehe www.swissmedicinfo.ch (10/2012).Zulassungsinhaberin: Grünenthal Pharma AG, 8756 Mitlödi, Tel. 055 647 31 31.

Wenn jede Minute zählt!

KEINE ZEIT FÜR

MIGRÄNE!KEINE ZEIT FÜR

MIGRÄNE!

Meetings

57

Grünenthal Pharma AG, 8756 Mitlödi

Gekürzte Fachinformation Zomig® nasal: C: Zolmitriptanum; Zomig® Filmtabl. zu 2,5 mg resp. Zomig® oro Lingualtabl. zu 2,5 mg resp. Zomig® nasal Nasalspray zu 2,5 mg oder 5 mg; Liste B. I: akute Migräne anfälle, Cluster-Kopfschmerz (nur Zomig® nasal). D: Migräne: 1x 2,5 mg (Zomig®, Zomig® oro oder Zomig® nasal) oder 1x 5 mg (Zomig® nasal); max. 10 mg/24 h. Cluster-Kopfschmerz: 1x 5 mg oder 10 mg Zomig® nasal. KI: Überempfindlichkeit, ischämische Herzerkrankungen, Myokardinfarkt in Vorgeschichte, koronare Vasospasmen (Prinzmetal-Angina), unzureichend eingestellte Hypertonie. V: Epilepsie, strukturelle Hirnschädigungen, Herzkrankheiten, Therapie mit Ergotaminen oder SSRI’s, Dosisreduktion bei gleichzeitiger Verabreichung von MAO-A-Hemmern, Phenylketonurie (Zomig® oro), Schwangerschaft. INT: Cimetidin, CYP1A2- Inhibitoren. UAW: sehr häufig: Geschmackstörungen (nur Zomig® nasal). Häufig: Schwindel, Kopfschmerzen, Schläfrigkeit, Wärmegefühl, Parästhesie und Hyperästhesie, Herzklopfen, Nasenbluten (nur Zomig® nasal), unangenehmes Gefühl in der Nasenhöhle (nur Zomig® nasal), Bauchschmerzen, Nausea, Erbrechen, Mundtrockenheit, Dysphagie, Muskelschwäche, Myalgie, Asthenie, Schwere-, Enge-, Schmerz- oder Druckgefühl in Hals, Nacken, Kiefer, Extremitäten und Thorax. Kassenzulässig. Liste B. Ausführliche Angaben siehe www.swissmedicinfo.ch (10/2012).Zulassungsinhaberin: Grünenthal Pharma AG, 8756 Mitlödi, Tel. 055 647 31 31.

Wenn jede Minute zählt!

KEINE ZEIT FÜR

MIGRÄNE!KEINE ZEIT FÜR

MIGRÄNE!

Tuesday, 22.10.2019, Hotel Starling Lausanne

Board meeting SNS13:30-16:45 | Meetingroom I +IIClinical directors meeting17:00-18:30 | Meetingroom I +II

Wednesday, 23.10.2019

Executive Board meeting SFCNS11:15-12:30 | Garden 4A

Board meeeting SSBN (SGVN)12:15-13:15 | Garden 3A

ELAN Investigator meeting12:15-13:30 | Garden 1A

Board meeting - Epi Suisse12:30-14:30 | Garden 5A

Delegates meeting SFCNS13:15-14:15 | Garden 5BC

IMSNQA - Quality13:15-14:15 | Garden 2A

Sitzung Schweizer Spitalneurologen13:45-14:30 | Raum 3A

Board meeting SSBP (SGBP)16:15-18:15 | Garden 3A

Board meeting SSNR (SGNR) 17:30-19:00 | Garden 2A

Board meeting SSNS (SGNC)17:30-19:00 | Garden 4A

General assembly SNS (SNG)17:30-19:00 | Auditorium C

Thursday, 24.10.2019

Board meeting SSNR (SGNRehab)10:00-12:00 | Garden 1A

Paritätische Kommission10:30-11:15 | Garden 3A

Sponsorpool11:30 - 12:30 | Garden 3A

General Assembly SSNR (SGNRehab)12:15 - 13:30 | Garden 1A

CTN Journal Editorial Board meeting13:00-14:30 | Garden 2A

Meetings

Meetings

59

Thursday, 24.10.2019 (continued)

Board meeting SSNC (SGKN)13:00-14:15 | Garden 4A

Klinische Epileptologen - Kick-off meeting13:00-14:00 | Garden 5A

General assembly SSNC (SGKN)17:30-18:45 | Auditorium C

General assembly SSNS (SGNC)17:30-18:45 | Garden 3BC

General Assembly SSNR (SGNR)17:30-18:45 | Garden 2BC

General Assembly SSBP (SGBP)17:30-18:45 | Garden 1BC

General Assembly SSBN (SGVN)17:30-18:45 | Garden 4BC

Board meeting OHBM AC Symposium19:00-19:45 | Garden 1A

General Assembly OHBM AC Symposium19:30-20:45 | Garden 1A

Friday, 25.10.2019

Joint strategy meeting SSNR, SFCNS, SNS, SSNS08:30-09:30, Garden 2A

Task Force “Sleep & Neurology”09:00-10:30 | Garden 4A

SFCNS Stroke Commission10:00-11:30 | Garden 1A

Board meeting SHS (SKG)10:00-11:00 | Garden 3A

AG Epilepsieforschung11:00-13:00 | Garden 2A

Joint meeting SFCNS executive board and Swiss Brain League12:00-12:45 | Garden 1A

Joint meeting SFCNS executive board and Swiss Society for Neuroscience council13:00-14:00 | Garden 1A

General assembly SHS (SKG)14:30-15:30 | Garden 3A

Meetings

60

Post

ers

Inserat?

* Résultats de l’étude d’extension Clarity Extension. 75,6 % des patients (n=98, sem. 120) continuent à ne pas présenter de poussées sans traitement supplémentaire par MAVENCLAD® lors des années 3 et 4; ** 16 à 20 jours, en fonction du poids corporel.

Références: 1 Information professionnelle de MAVENCLAD®, www.swissmedicinfo.ch, Mise à jour de l’information: avril 2019 2 Giovannoni G et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2018; 24(12):1594-1604

MAVENCLAD® (10 mg de cladribine). I: Patients adultes atteints de sclérose en plaques (SEP) récurrente-rémittente très active, définie par des constats cliniques ou d‘imagerie médicale. PO: Dose de 3,5 mg/kg de poids corporel, répartie sur 2 ans sous forme d‘un cycle de traitement de 1,75 mg/kg par an. CI: Hypersensibilité à la cladribine ou à l‘un des excipients. Infection par le virus de l‘immunodéficience humaine (VIH). Infection sévère active, infection chronique active (p.ex. tuberculose ou hépatite). Instauration du traitement chez les patients immunodéprimés. Présence d‘un cancer actif. Antécédent de leucoencéphalopathie multifocale progressive. Insuffisance rénale modérée ou sévère. Enfants et adolescents de moins de 18 ans. Grossesse et allaitement. PR: De façon générale: non recommandé chez les patients dont la maladie est inactive ou stabilisée sous un traitement établi. Ne pas administrer plus de 2 cycles de traitement annuels en 4 ans. Surveillance hématologique: le taux de lymphocytes doit être vérifié avant le début du traitement par Mavenclad les années 1 et 2 ainsi que 2 et 6 mois après le début de chaque cycle de traitement administré. Infections: La cladribine peut affaiblir les défenses immunitaires du patient et éventuellement accroître le risque d‘infections. Les patients dont le taux de lymphocytes est inférieur à 500 cellules/mm3 doivent être surveillés activement quant aux signes et symptômes d‘infections, en particulier du zona. Cancers: La cladribine interfère avec la synthèse d‘ADN et a un effet immunosuppresseur. Contraception: Des méthodes fiables de contraception doivent être utilisées pendant le traitement par la cladribine et encore au moins 6 mois après la dernière dose. Transfusions sanguines: chez les patients devant recevoir des transfusions sanguines, il est recommandé d‘irradier les produits sanguins avant la transfusion. Passage d’un autre traitement à cladribine et inversement: le mécanisme d‘action et la durée d‘action de l‘autre médicament doivent être pris en compte avant le début du traitement par Mavenclad. Affections rénales: Mavenclad ne doit pas être utilisé chez les patients présentant une insuffisance rénale modérée ou sévère. Affections hépatiques: Mavenclad n‘est pas recommandé chez les patients présentant une insuffisance hépatique modérée ou sévère. Intolérance au fructose: les patients présentant une intolérance au fructose ne doivent pas prendre Mavenclad. IA: Mavenclad contient de l’hydroxypropylbétadex qui peut éventuellement former des complexes avec d‘autres médicaments et accroître ainsi leur biodisponibilité. Médicaments hématotoxiques ou immunosuppresseurs (méthotrexate, cyclophosphamide, ciclosporine, azathioprine, corticostéroïdes). Autres agents modificateurs de la maladie. Médicaments hématotoxiques (carbamazépine). Vaccins vivants ou vivants atténués. Inhibiteurs puissants des transporteurs ENT1, CNT3 et BCRP (p. ex. dilazep, nifédipine, nimodipine, cilostazol, sulindac, réserpine). Inducteurs puissants des transporteurs BCRP et P-gp (p.ex. corticostéroïdes, rifampicine, millepertuis). Contraceptifs hormonaux. EI les plus fréquents: lymphopénie, herpès buccal, zona touchant un dermatome, taux réduit de neutrophiles, éruption cutanée, alopécie. P: Mavenclad 10 mg: 1, 4 ou 6 comprimés. [A] Pour des informations plus détaillées, veuillez consulter www.swissmedicinfo.ch. AVR19

Merck (Suisse) SA, Chamerstrasse 174, 6300 ZougCH

/CLA

/021

9/0

010

a(1)

Années 1 + 220** jours de prise

au maximum1

Années 3 + 4 75%* de patients exempts

de poussées sans traitement supplémentaire1,2

Welcome toMAVENCLAD®

dès maintenant remboursé

61

Posters

Poster & e-Posters

ePoster SNS

P63

P64

P65

P66

P67

P68

P69

P70

P71

Serum neurofilament light chain is associated with progressive cerebral small vessel diseaseN Peters, e van leijsen, A Tuladhar, C Barro, m konieczny, m ewers, P Lyrer, S Engelter, J Kuhle, m duering, f de leeuw | Basel, CH; Nijmegen, NL; Munich, DE

Relapsing lymphopenia after dimethyl fumarate discontinuation: an observational study in the Lausanne MS cohort.S Borrelli, G Le Goff, A Mathias, R Du Pasquier, M Théaudin, C Pot | Lausanne, CH

Diagnosis of iNPH only through longterm drainage of spinal fluid. A case report.L Bohlen, D Zieglgänsberger, B Tettenborn, C Mosimann, S Simmen, S Hägele-Link, F Brugger | St. Gallen, CH; Grabs, CH

Recurrence of multiple sclerosis activity after fingolimod discontinuation is not rare in older patients previously stable on treatment.V Pantazou, C Pot-Kreis, R Du Pasquier, M Théaudin | Lausanne, CH

Comparative outcomes after cerebrovascular accidents from atherosclerosis versus dissection of extracranial and intracranial arteries at 90 daysI Ahmed, SG Bulchandani | Kansas City, US

Age at disease onset and clinical outcomes in patients with multiple sclerosis on immunomodulatory treatmentV Von Wyl, B Décard, P Benkert, J Lorscheider, P Hänni, C Lienert, J Kuhle, T Derfuss, L Kappos, Ö Yaldizli | Zürich, CH; Basel, CH; Solothurn, CH; Walzenhausen, CH

Higher serum neurofilament light chain levels are associated with lower self-reported quality of life in the Swiss MS Registry and the Swiss MS Cohort-StudyM Kaufmann, A Salmen, CP Kamm, A Chan, S Schippling, P Calabrese, D Leppert, C Gobbi, J Kuhle, V von Wyl | Zurich, CH; Bern, CH; Lucerne, CH; Basel, CH; Lugano, CH

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) studyCP Kamm, L Barin, A Salmen, S Schippling, P Calabrese, V von Wyl | Lucerne, CH; Zurich, CH; Bern, CH; Basel, CH

Long-term Effect of Fingolimod in Reducing Blood Neurofilament Light Levels in Patients with Relapsing-remitting Multiple SclerosisJ Cohen, L Kappos, N Tenenbaum, A Couturier, H Kropshofer, D Tomic, J Kuhle | Cleveland, US; Basel, CH; East Hanover, US

P1-P6 YouCLIN-Award: Page 21-23P7-P18 ePoster Session SNS: Page 27-28 P20-P30 ePoster Session SSNS & SSNR: Page 29-31P31-P42 ePoster Session SLaE & SSCN: Page 31-33P43-P50 ePoster Session SSBP & SSBN: Page 33-35P51-P62 ePoster Session SSNP & SSNPath: Page 35-37

62

Post

ers

ePoster SNS

P72

P73

P74

P75

P76

P77

P78

P79

P80

P81

Accuracy of the pupillary unrest index for assessing fitness to driveD Schreier, D Andres, A Hertig-Godeschalk, A Mathis, C Roth, J Mathis | Bern, CH

Head to head comparison of clinical efficacy of dimethyl fumarate versus fingolimod in different pretreatment situations: A retrospective European real world studyL Diem, A Daponte, O Findling, R Gold, A Miclea, M Briner, A Salmen, A Chan, ME Evangelopoulos, R Hoepner | Bern, CH; Athens, GR; Aarau, CH; Bochum, CH

Sleep-wake disturbances after ischemic stroke or transient ischemic attacks as predictors of new cardio-cerebro-vascular events and outcomeSB Duss, C Bernasconi, A Steck, M Dekkers, F Alexiev, MH Schmidt, C Bassetti | Bern, CH

New or enlarging T2 weighted lesions in the white matter near to the ventricle wall and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosisT Sinnecker, E Ruberte, S Schädelin, V Canova, M Amann, Y Naegelin, I Penner, J Kuhle, B Décard, T Derfuss, S Andermatt, P Cattin, L Kappos, C Granziera, J Wuerfel, S Magon, Ö Yaldizli | Basel, CH; Düsseldorf, DE

Progression Independent of Relapse Activity (Pira) in relapsing-remitting multiple sclerosis patients on first-line immunomodulatory treatment with fingolimod vs. platform injectablesV Von Wyl, P Benkert, J Lorscheider, P Hänni, C Lienert, B Décard, J Kuhle, T Derfuss, L Kappos, Ö Yaldizli | Basel, CH; Solothurn, CH; Walzenhausen, CH

Improvements in balance control for multiple sclerosis patients with vibro-tactile biofeedback of trunk swayJ Allum, C Schouenborg, N Lutz, H Rust, B Fischer-Barnicol, V Haller, J Kuhle, T Derfuss, L Kappos, Ö Yaldizli | Basel, CH

Atrophy of the Lateral Geniculate Nucleus after Optic Neuritis in Neuromyelitis Optica Spectrum Disorders: a longitudinal studyA Papadopoulou, FC Oertel, C Chien, J Kuchling, H Zimmermann, N Siebert, M D' Souza, S Asseyer, J Bellmann-Strobl, K Ruprecht, MM Chakravarty, M Scheel, S Magon, J Würfel, F Paul, AU Brandt | Basel, CH; Berlin, DE; Montreal, CA

A framework for estimating the burden of chronic diseases: Design and application in the context of multiple sclerosisM Kaufmann, MA Puhan, J Kuhle, Ö Yaldizli, T Magnusson, CP Kamm, P Calabrese, V von Wyl | Zurich, CH; Basel, CH; Zuchwil, CH; Lucerne, CH

Ageing with Multiple Sclerosis: The role of calendar age and disease duration for disease outcomes and co-morbidity occurrence in the Swiss Multiple Sclerosis RegistryA Salmen, A Chan, P Calabrese, CP Kamm, J Kuhle, S Schippling, V von Wyl | Bern, CH; Lucerne, CH; Basel, CH; Zurich, CH

Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study DesignD Leppert, G Giovannoni, L Airas, R Bove, A Boyko, G Cutter, J Hobart, J Kuhle, J Oh, C Tur, M Garas, F Model, M Manfrini, JS Wolinsky | Basel, CH; London, GB; Turku, FI; San Francisco, CA, US; Moscow, RU; Birmingham, AL, US; Plymouth, Devon, GB; Toronto, CA, US; Houston, TX, US

63

Posters

ePoster SNS

Atypical Anti-MOG syndrome with a pseudotumor cerebri-like presentation – a case reportTTH Pham, T Kahles, M Tröger, O Findling, K Nedeltchev, L Achtnichts | Aarau, CH

Combined central and peripheral demyelination (CCPD): a case reportS Corbiere, A Felbecker, W Julia | St. Gallen

Model (PHREND®) for personalized prediction of treatment response in relapsing remitting multiple sclerosis (RRMS)V Tozzi, E Stühler, F Lionetto, Y Heer, E Jules, P van Hövell, S Braune, A Bergmann | Zürich, CH; Neuburg an der Donau, DE

Orofacial pain in dental practice: prevalence of neuropathic and musculoskeletal painT Badel, V Basic Kes, N Lukic, I Savic Pavicin, M Lisak, D Zadravec | Zagreb, HR; Kroatien, HR; Zürich, CH

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple SclerosisL Kappos, SL Hauser, X Montalban, R Hughes, J McNamara, A Pradhan, D Wormser, H Koendgen, JS Wolinsky | Basel, CH; San Francisco, CA, US; Barcelona, ES; Cambridge, GB; South San Francisco, CA, US; Houston, TX, US

The Medical Informatics Platform (MIP): an innovative tool for sharing patients’ BIG data in clinical neuroscience across Europe.T Phenix, L Claude, M Nasuti, MG Spuhler, E Borcel, S Cappa, C Dhondt, G Frisoni, I Foufoulas, F Gaillard, Y Ioannidis, AM Karampatsis, K Karozos, S Karvounari, K Kechagias, M Leroy, E Mailli, M Marcus, F Nasuti, E Panagiotopoulou, F Pasquier, N Perrin, B Rakotomiaramanana, A Redolfi, J Sakellariou, D Steinberg, S Schweighauser, V Vassalos, E Zacharia, J Demonet, P Ryvlin | Lausanne, CH; Pavia, IT; Geneva, CH; Athens, GR; Lille, FR; Tel Aviv, IL; Brescia, IT; Tel Aviv, IL

Patient reported outcomes identify factors that influence quality of life in MS patients treated with natalizumab. A post hoc analysis.L Achtnichts, C Zecca, C Kamm, O Findling, S Müller, E Villiger-Borter, K Nedeltchev | Aarau, CH; Lugano, CH; Luzern, CH; Aarau, CH; St. Gallen, CH; Baar, CH

Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup AnalysisB Ralph, R Fox, D Tomic, B Cree, P Vermersch, G Giovannoni, A Bar-Or, R Gold, S Ritter, G Karlsson, C Wolf, L Kappos | Buffalo, US; Cleveland, US; Basel, CH; San Francisco, US; Lille, FR; London, GB; Philadelphia, US; Bochum, DE; Uccle, BE

New-onset gaze-evoked nystagmus as an early clinical sign of thiamine deficiency – a case reportB Wiggli, S Kapitza, F Ahlhelm, AA Tarnutzer | Baden, CH

Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurementsT Sinnecker, S Schädelin, E Ruberte, V Canova, M Amann, S Magon, J Lieb, Y Naegelin, J Kuhle, T Derfuss, L Kappos, J Wuerfel, C Granziera, Ö Yaldizli | Basel, CH

P82

P83

P84

P85

P86

P87

P88

P89

P90

P91

64

Post

ers

ePoster SNS

ePoster SSNS

P92

P93

P94

P95

P96

P97

P98

P99

P100

P101

P102

Transcallosal inhibition and mirror movements in amyotrophic lateral sclerosisA Hübers | Genève, CH

Rare variant of Guillain-Barré syndrome after chikungunya viral fever: A Case ReportSH Shaikh, S Khan | Karachi, PK

NEDA-3 durability in patients receiving Cladribine TabletsG Giovannoni, A Galazka, B Keller, D Jack | London, UK; Darmstadt, DE

Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval dataS Cook, G Giovannoni, T Leist, G Comi, S Syed, A Nolting, A Galazka, D Damian, R Schick | Newark NJ, US; London, UK; Philadelphia PA, US; Milan, IT; Billerica MA, US; Darmstadt, DE

A series of cases with PERM in association with GAD, NMDA, LGI1 and other antibodiesI Barbov, G Kalcev, F Stojkovska | Skopje, MK

Validation of the Scoring Algorithm for a Novel Integrative Secondary Progressive Multiple Sclerosis (SPMS) Screening ToolT Ziemssen, D Piani Meier, B Bennett, C Johnson, K Tinsley, A Trigg, F Dahlke, D Tomic, C Tolley, M S. Freedman | Dresden, DE; Basel, CH; Macclesfield, GB; Macclesfield, GB; Ottowa, CA

Ultra-early and periinterventional angiographic cerebral vasospasm after aneurysmal sub-arachnoid hemorrhage predicts early onset of delayed cerebral vasospasm, delayed cerebral ischemia, and poor outcome.S Marbacher, B Bircher, DR Vogt, M Diepers, L Remonda, J Fandino | Aarau, CH; Basel, CH

Outcome and Course of Sequelae of acromegaly after treatment of human growth hormone excess (AcroSequelae) - a SwissPit studyJ Brun, L Mariani, E Christ, P Schütz, J Fandino, S Berkmann | Aarau, CH; Basel, CH

An endovascular assisted non-occlusive cerebral high flow bypass – a technical feasibility study in a rabbit model.F Strange, A Spiessberger, BE Gruter, S Wanderer, M Diepers, J Fandino, L Remonda, J Anon, S Marbacher | Aarau, CH

Postoperative course and outcome of optic chiasm syndrome after pituitary surgery - A SwissPit StudyM Hofer, J Fandino, S Berkmann | Aarau, CH

Anatomical Features of Primary Brain Tumors affect Seizure Risk and SemiologyK Akeret, C Serra, O Rafi, VE Staartjes, J Fierstra, J Fierstra, D Bellut, N Maldaner, LL Imbach, F Wolpert, R Poryazova, L Regli, N Krayenbühl | Zurich, CH

65

Posters

ePoster SSNS

P103

P104

P105

P106

P107

P108

P109

P110

P111

P112

P113

Multidimensional Personalized Response Assessment to Microglia Modulators in Gioblastoma BioreactorsT Shekarian, AT Wachnowicz, T Martins, J Flammer, C Paganetti, MG Muraro, C Schuerch, G Hutter | Basel, CH; Stanford, US

Patterns of Care: Burr-Hole Cover Application for Chronic Subdural Hematoma TrepanationJ Velz, F Vasella, K Akeret, SF Dias, E Jehli, O Bozinov, L Regli, MR Germans, MN Stienen | Zurich, CH

Posterior fossa lesion resection and post-operative hydrocephalus: a multicenter retrospective study for risk factor identification and state-of-art treatment methodsA Moiraghi, A Saladino, L Paun, TR Meling, A Mangraviti, A Bartoli, L Mattei, S Marco, P Ferroli, A Franzini, P Bijlenga, S Momjian, P Borrelli, K Schaller, F DiMeco | Geneva, CH; Milano, IT

Direct stimulation of the Söring ultrasonic aspirator handpiece for subcortical motor mapping: feasibility and safety of a new techniqueC Goga, K Tizi, A Bartoli, N Bérard, S Momjian, K Schaller, C Boëx | Geneva, CH

Does Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS TLIF) results in lower fusion rates? A retrospective study with 2 years follow-upP Scarone | Lugano, CH

Nicotine substitution in the acute phase of subarachnoid haemorrhage: What are the Euro-pean practices?C Eisenring, R Kockro, I Jacot Sadowski, B Schatlo, D Nanchen | Zürich, CH; Lausanne, CH; Göttingen, DE

Microsurgical Creation of Complex Bifurcation Aneurysms with Different Wall Conditions in New Zealand White Rabbits – Introducing the Surgical Technique in a New Animal ModelS Wanderer, B Gruter, C Waltenspuel, F Strange, S Sivanrupan, M von Gunten, J Anon, HR Widmer, D Casoni, L Anderegggen, J Fandino, S Marbacher | Aarau, CH; Bern, CH

Microglia modulation in combination with tumor-targeting CAR T cell therapy for the treat-ment of glioblastomaT Martins, H Baidarjad, T Shekarian, M.-F. Ritz, G Hutter | Basel, CH

Association of persistent pain and implant malposition in sacroiliac joint fusion surgeryC Eisenring, B Schatlo | Zürich, CH; Göttingen, GI

Posterior Fossa Meningiomas: Perioperative Predictors of Extent of Resection, Overall Survival and Progression-Free Survival.MV Corniola, J Lemée, M Da Broi, H Joswig, K Schaller, E Helseth, T Meling | Genève, CH; Oslo, NO; Geneva, CH

Objective functional assessment using the «Timed-Up and Go» test in patients with lumbar spinal stenosisMN Stienen, N Maldaner, H Joswig, MV Corniola, D Bellut, P Prömmel, L Regli, A Weyerbrock, K Schaller, OP Gautschi | Zürich, CH; St.Gallen, CH; Geneva, CH; Lucerne, CH

66

Post

ers

ePoster SSNS

P114

P115

P 116

P117

P118

P119

P120

P121

P122

P123

P124

Objective measures of functional impairment for degenerative diseases of the lumbar spine: a systematic review of the literatureMN Stienen, AL Ho, VE Staartjes, N Maldaner, A Veeravagu, A Desai, OP Gautschi, D Bellut, L Regli, JK Ratliff, J Park | Zürich, CH; Stanford, US; St.Gallen, CH; Lucerne, CH

Conservative and surgical outcome of non-neoplastic cystic pathologies of the pituitary - A SwissPit StudyP Schwyzer, P Schütz, L Remonda, J Fandino, S Berkmann | Aarau, CH

Thoracolumbar Corpectomy/spondylectomy for spinal metastasis: a pooled analysis comparing the outcome of seven different surgical approaches.A Spiessberger, V Arvind, B Grüter, S Cho | New York, US; Aarau, CH

Cerebral aneurysms in young children: long-term clinicalA Amelot, G Saliou, S Benichi, Q Alias, G Boulouis, M Zerah, N Aghakani, A Ozanne, T Blauwblomme, O Naggara | Paris, FR; Lausanne, CH; Bicetre, FR

Extent of resection (EOR) in inactive pituitary macroadenomas; microscopic versus endoscopic technique. A preliminary report on 62 consecutive microsurgical patients after volumetric independent assessment.N Eberhard, B Westermann, L Mariani | Basel, CH

Posterior Fossa Meningiomas: Perioperative Predictors of Extent of Resection, Overall Survival and Progression-Free Survival.M Corniola, J Lemée, H Joswig, M Da Broi, K Schaller, E Helseth, T Meling | Geneva, CH; Oslo, NO

Lateral Sphenoid Wing Meningiomas Without Bone Invasion – Still Skull Base Surgery?M Corniola, J Lemée, K Schaller, T Meling | Geneva, CH

The Zurich Pituitary Score predicts utility of intraoperative high-field magnetic resonance imaging in transsphenoidal pituitary adenoma surgeryVE Staartjes, C Serra, N Maldaner, G Muscas, O Tschopp, MB Soyka, D Holzmann, L Regli | Zurich, CH

Early ventriculo peritoneal shunting in aneurysmal subarachnoid hemorrhage is associated with a lower rate of nosocomial meningitisDM Croci, M Dalolio, D Zumofen, R Guzman, L Mariani, M Roethlisberger | Lugano, CH; Basel, CH

Task-free evaluation of postoperative outcome in neurosurgery using day-to-day smartphone behaviorK Akeret, F Vasella, O Zindel-Geisseler, N Dannecker, P Brugger, L Regli, MN Stienen, A Gosh | Zurich, CH; Leiden, NL

Spinal drop metastases of glioblastoma multiforme before and after introduction of the“Stupp” schemeM Albrecht | Kiel, DE

67

Posters

ePoster SSNS

P125

P126

P127

P128

P129

P130

P131

P132

P133

P134

P135

P136

Reliability Measures of the 6-Minute Walking Test Smartphone Application (6WT app)MN Stienen, OP Gautschi, VE Staartjes, N Maldaner, A Veeravagu, A Desai, CC Zygourakis, J Park, L Regli, JK Ratliff | Zurich, CH; Lucerne, CH; St.Gallen, CH; Stanford, US

Comparison of intra- and postoperative three-dimensional digital subtraction angiography in evaluation of the surgical result after intracranial aneurysm treatmentS Marbacher, J Kienzler, I Mendelowitsch, D D`Alonzo, L Andereggen, M Diepers, L Remonda, J Fandino | Aarau, CH

Preclinical extracranial aneurysm models for the study and treatment of intracranial aneu-rysms: A systematic review.S Marbacher, F Strange, J Fandino | Aarau, CH

Comparison of Aneurysm Patency and Mural Inflammation in an Arterial Rabbit Sidewall and Bifurcation Aneurysm Model under Consideration of Different Wall ConditionsB Grüter, S Wanderer, F Strange, S Sivanrupan, M von Gunten, L Remonda, HR Widmer, D Coluc-cia, J Fandino, S Marbacher | Aarau, CH; Bern, CH; Ittigen, CH

Systematic Review and Meta-analysis of Methodological Quality in in-vivo Animal Studies of Subarachnoid HemorrhageB Grüter, D Croci, S Schöpf, E Nevzati, D d′Alonzo, J Lattmann, T Roth, B Bircher, C Muroi, G Dutilh, HR Widmer, J Fandino, S Marbacher | Aarau, CH; Bern, CH

Predictive Analytics in Pituitary Surgery based on Machine LearningVE Staartjes, C Serra, G Muscas, N Maldaner, K Akeret, B van Niftrik, J Fierstra, L Regli | Zurich, CH

Frameless navigated transcerebellar brainstem biopsy: Case report and review of the literatureF Metin, S Marbacher, J Fandino | Aarau, CH

Outcome of Dermabond (TM) Prineo (TM) for Wound Closure after Intradural Spine Surgery in Children – preliminary results of eight consecutive patientsN Eberhard, S Stricker, M Licci, R Guzman, J Soleman | Basel, CH

Preclinical intracranial aneurysm models for the study and treatment of intracranial aneu-rysms: A systematic review.F Strange, BE Gruter, J Fandino, S Marbacher | Aarau, CH

ACCURACY OF C1-C2-C3 SCREW FIXATION USING INTRAOPERATIVE 3D FLUOROSCOPY – NAVIGATIONG Jannelli, A Moiraghi, A Bartoli, E Tessitore | Geneva, CH

Enhanced Recovery After Spine Surgery and Outpatient Sugery: The Patients’ Perspective.M Corniola, K Schaller, E Tessitore | Geneva, CH

Inappropriate oxytocin secretion precedes SIADH-related hyponatremia after transsphenoidal pituitary surgeryP Constanthin, N Isidor, S De Seigneux, S Momjian | Geneva, CH

68

Post

ers

ePoster SSNS

P137

P138

P139

P140

P142

P143

P144

P145

P146

P147

P148

P149

SEM analysis of experimentally induced aneurysms in rats at different time points during aneurysm formationL Schwyzer, S Marbacher, J Fandino, A Dumont | Aarau, CH; New Orleans, US

The Swiss Pituitary Registry 2019 - An update on the first national registry for pituitary tumors: SwissPitS Berkmann, M Röthlisberger, K Kothbauer, S Fischli, H Richter, S Bilz, L Regli, P Schütz | Aarau, CH; Basel, CH; Luzern, CH; St. Gallen, CH; Zürich, CH

The prophylactic use of low molecular weight heparin in patients with external ventricular drainsE Bulgen, G Higginbotham, F Saeed | Leeds (GB)

Proteomic map of glioma biopsies reveals functional defects in endocytosisD Buser, J Boulay, M Ritz, C Tostado, S Frank, M Spiess, P Jenö, G Hutter | Basel, CH

Glioblastoma Diagnosis: Communicating with Patients and RelativesE Müller, Carline Fuchs-Perren, Javier Fandino, Peter J. Schulz | Lugano, Aarau, CH

Assessment of a novel stereotactic frame-based setting for magnetic resonance imaging-guided laser-induced thermal therapyM Oertel, L Regli, O Bozinov | Zurich, CH

Flat panel computer tomography in Hybrid operating room for neurological intervention: A phantom and retrospective studyA El Mekabaty, C Aberle, K Blackham, D Zumofen | Basel, CH

Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing’s syndromeL Andereggen, J Gralla, G Schroth, P Mordasini, R Andres, W Hans Rudolf, M Luedi, J Beck, L Mariani, C Ozdoba, E Christ | Aarau, CH; Bern, CH; Basel, CH

HR 1H NMR Spectroscopy Intervertebral Disc Degeneration Imaging in the Cervical SpineM Arrighi, R Bostelmann, D Donaldson, A Petridis, H.-J. Steiger, K Koch, R Hartmann, D Will-bold | Düsseldorf, DE

Multidisciplinary management of benign aggressive vertebral hemangiomas in a hybrid room facility: a case-series.MV Corniola, C Schonauer, G Bernava, P Machi, H Yilmaz, K Schaller, E Tessitore | Genève, CH; Napoli, IT;

DUAL PATHOLOGIES: PIAL ARTERIOVENOUS FISTULA IN COMBINATION WITH AN ARTERIO-VENOUS MALFORMATIONG Jannelli, H Joswig, G Bernava, T Meling, P Bijlenga | Geneva, CH

Anterior compressive cervicothoracic pseudomeningocele as a rare manifestation of idiopathic intrathecal hypotension: a case report and literature reviewR Gondar, I Brouze, D Valsecchi, G Maestretti | Fribourg, CH

69

Posters

ePoster SSNS

P150

P151

P152

P153

P154

P155

P156

P157

Multidisciplinary management of benign aggressive vertebral hemangiomas in a hybrid room facility: a case-series.M Corniola, C Schonauer, G Bernava, P Machi, H Yilmaz, K Schaller, E Tessitore | Geneva, CH; Pozzuoli, IT

Improving intraoperative evoked potentials at short latency by a novel neuro-stimulation technology.J Sarnthein, M Tomilov, M Baag, O Bozinov | Zürich, CH; Emmendingen, DE

Technical and non-technical skills training by combined simulation and cadaver lab dissection: the MiGe courseA Moiraghi, A Perin, G Carone, R Ayadi, A Rocca, G Enrico, T Galbiati, J Godjevac, TR Meling, F DiMeco, K Schaller | Geneva, CH; Milano, IT; Verona, IT

Studying Brain Energy Metabolism on a Single Cell Level in vivo Using Optogenetics and Two-Photon Imaging F Mozaffari, M Wyss, M Zuend, B Weber | Basel, CH; Zurich, CH

Osteoblastoma in third cervical vertebra: Case reportM Rüedi de Paiva, M Bergamo Lomaz, FR de Tavares Canto | Yverdon-les-Bains, CH; Uberlândia, BR

Three-dimensional visualization of aneurysm wall calcification by cerebral angiography: Technical case reportL Andereggen, S Bäbler, J Anon, L Remonda, J Fandino, S Marbacher | Aarau, CH

Biochemical in-vivo imaging of Intervertebral Disc Degeneration with HR 1H NMR Spectroscopy in Cervical SpineM Arrighi, K Koch, D Donaldson, M Suresh, A Petridis, H.-J. Steiger, R Bostelmann | Düsseldorf, DE

Novel soft subdural electrodes versus standard clinical arrays: a comparative pilot cadaver studyG Zegarek, A May, P Constanthin, F Fallegger, N Vachicouras, G Schiavone, L Serex, J Bourely, M Vargas, S Lacour, D Van Roost, K Schaller | Geneva, CH; Lausanne, CH; Ghent, BE

70

Post

ers

P158

P159

P160

P161

P162

P163

P164

P165

P166

P167

P168

P169

P170

Assessment of velocity reduction after flow diverter stent implantations using 4D PCMRIP Reymond, O Brina, P Bouillot, S Luthman, C Santarosa, M Farhat, K Lovblad, P Machi, B Delattre, V Pereira, MI Vargas | Genève, CH; Lausanne, CH; Toronto, CA

Angioplasty using Drug-coated balloon in Symptomatic Intracranial High-grade Stenosis: A Mono-Center Cohort Study of 26 PatientsP Gruber, J Berberat, T Kahles, J Anon, M Diepers, K Nedeltchev, L Remonda | Aarau, CH

“Armed Kyphoplasty”: An Indirect Central Canal Decompression Technique in Burst-FracturesA Venier, L Roccatagliata, M Isalberti, P Scarone, DE Kuhlen, M Reinert, A Cianfoni | Lugano, CH

A1-A2 flow diverters placement for ACom aneurysms treatment is associated with a high risk of perforating branch infarctionS Bacher, F Puccinelli, SD Hajdu, PJ Mosimann, G Saliou, B Bartolini | Lausanne, CH; Bern, CH

Posterior communicating artery retrograde approach for intra-arterial super-selective treatment of RetinoblastomaGP Marie, C Stathopoulos, B Bartolini, G Saliou, F Puccinelli, S Hajdu | Lausanne, CH

Intra-Arterial Chemotherapy for Retinoblastoma: 10 years experience of a single center.F Puccinelli, B Bartolini, S HAJDU, C Stathopoulos, PJ Mosimann, M Beck-Popovic, F Munier, G Saliou | Lausanne, CH; Bern, CH

Achievable Aspiration Flow Rates with Large Balloon Guide Catheters during Carotid Artery StentingT Schubert, L Rivera, A Roldan-Alzate, D Consigny, L Leitner, C Strother, B Aagaard-Kienitz | Zürich, CH; Madison, WI, US

Cerebrospinal fluid dynamics in the optic nerve subarachnoid space using diffusion weighted MRI in patients with idiopathic intracranial hypertensionJ Berberat, P Gruber, K Lövblad, L Remonda, H Killer | Aarau, CH; Geneva, CH

Feasibility and Safety of Angioplasty using Drug-coated Balloons in Ostial Vertebral Artery Stenosis: A Single-center Case-SeriesP Gruber, J Berberat, T Kahles, J Anon, M Diepers, K Nedeltchev, L Remonda | Aarau, CH

Computer processing of a large number of slices for pattern recognition in special areas of the brainZ Zaleshina, A Zaleshin | Dolgoprudny, RU

what neuroradiologists should know about notochordal remnants: normal variants and pathologyL Etienne, F Aïkaterini, J Baiao Boto, A Regnaud, M Vargas, K Lovblad | Geneva, CH

Diagnostic value of susceptibility weighted imaging in clinical practiceA Regnaud, J Boto, A Fitsiori, L Etienne, K Lövblad, MI Vargas | Geneva, CH

Micro-CT and dual-energy CT of the thrombus in acute ischemic stroke patients undergoing thrombectomyD Botta, P Machi, M Isabel Vargas, P.-A. Poletti, I Wanke, D Rüfenacht, M Muster, K.-O. Lövblad | Basel, Zürich, CH

ePoster SSNR

71

Posters

ePoster SSNR

ePoster SLaE

ePoster SSCN

Imaging of arachnoid cysts and webs of the spinal canalA Fitsiori, J Baiao Boto, L Etienne, A Regnaud, K Lovblad, E Tessitore, M Vargas | Geneva, CH

Dose-optimized computed tomography of the cervical spine in patients with shoulder pull-down: is image quality comparable with a standard dose protocol in an emergency setting?M Tozakidou, S Yang, BK Kovacs, Z Szucs-Farkas, U Studler, S Schindera, A Hirschmann | Hamburg, DE; Basel, CH; Aarau, CH

A neuromorphic system-on-a-chip detecting High-Frequency Oscillations in electrocorticographyM Sharifshazileh, K Burelo, T Fedele, G Indiveri, J Sarnthein | Zürich, CH; Moscow, RU

Mu oscillations during emotional face processing in epilepsy patients and normal controlsT Sollfrank, L Kegel, P Hilfiker, H Jokeit, D Mersch, A Rey, T Grunwald | Zurich, CH

Somatosensory Profiles in Patients with non Specific Neck Arm Pain with and without positive Neurodynamic TestsK Böttger, B Tampin, N Ballenberger, G Landmann, L Stockinger, AB Schmid | Nottwil, CH; Perth, AU; Osnabrueck, DE; Oxford, GB

Muscle hypertrophy in a patient with multifocal motor neuropathy (MMN) – a case reportL Schilg-Hafer, D Leupold, A Felbecker | St. Gallen, CH; Parkville, AU

Low-intensity sinusoidal electrical stimulation in patients with peripheral neuropathic painG Landmann, L Stockinger, M Schmelz, R Rukwied | Nottwil, CH; Mannheim, DE

The relation between neuronal firing, local field potentials and hemodynamic activity in the human amygdala in response to an aversive dynamic visual stimuliT Fedele, A Tzovara, B Steiger, P Hilfiker, T Grunwald, L Stieglitz, H Jokeit, J Sarnthein | Moscow, RU; Zürich, CH

EVALUATION OF TEMPORARAL INTEGRATION OF CENTRAL AUDITORY PROCESSING IN PATIENTS WITH TINNITUSV Oliveira, R Meneses, N Trigueiros | Porto, PT; Senhora da Hora, PT

Debilitating and Inoperable Common Peroneal Nerve Rupture Following Minor Knee Trauma: A case reportD Uffer, A Felbecker | St. Gallen, CH

Patients’ Real-World Experience with Erenumab (Aimovig®) in the Prevention of Migraine in SwitzerlandR Agosti, L Aeschlimann, K Doering | Zurich, CH

P171

P172

P173

P174

P175

P176

P177

P178

P179

P180

P181

72

Post

ers

ePoster SHS

ePoster SSNP

P182

P183

P184

P185

P186

P187

P188

P189

P190

The SQUARE study design: A multi-centric, non-interventional study to evaluate the impact of erenumab on quality of life in a real-world population with migraine.ME Arzt, I Meyer, C Koblbauer, S Rohrer, AR Gantenbein | Rotkreuz, CH; Walding, AT; Bad Zurzach, CH

Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY StudyU Reuter, P Goadsby, M Lantéri-Minet, P Hours-Zesiger, C Fernandes, M Ferrari, J Klatt, ME Arzt | Berlin, DE; San Francisco, US; Nice, FR; Basel, CH; Leiden, NL; Basel, CH; Rotkreuz, CH

Benefit-Risk Assessment of Galcanezumab versus Placebo for the Treatment of Episodic and Chronic Migraine: Results from EVOLVE-1, EVOLVE-2, and REGAIN Clinical TrialsD Ruff, A Tockhorn-Heidenreich, S Foster, R Nichols, V Stauffer | Indianapolis, US

Patients’ Experience with Medical Cannabis in the Treatment of MigraineR Agosti, L Aeschlimann, K Doering | Zurich, CH

FIREFISH Part 1: 1-year results on motor function in babies with Type 1 SMAA Klein, G Baranello, L Servais, JW Day, N Deconinck, E Mercuri, B Darras, R Masson, H Kletzl, Y Cleary, M El-Khairi, T Seabrook, M Gerber, C Nguyen, K Gelblin, K Gorni | Basel, CH; Milan, IT; Paris, FR; Palo Alto, CA, US; Brussels, BE; Rome, IT; Boston, MA, US; Welwyn Garden City, GB

Resting State Thalamocortical Networks during Early Lifespan and their Relation to Cognitive PerformanceL Steiner, A Federspiel, R Wiest, N Slavova, S Grunt, R Everts, M Steinlin | Bern, CH

Long-term follow-up of vein of Galen malformation: improvement in management is still neededH Taffin, H Maurey, A Ozanne, P Durand, B Husson, C Adamsbaum, K Deiva, G Saliou | Bicetre, FR; Lausanne, CH

Update from SUNFISH Part 1: Safety, tolerability and PK/PD from the dose-finding study, including exploratory efficacy data in patients with Type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916)R Masson, E Mercuri, G Baranello, J Kirschner, L Servais, N Goemans, MC Pera, J Buchbjerg, W Yeung, H Kletzl, M Gerber, Y Cleary, K Gorni | Milan, IT; Rome, IT; Freiburg, DE; Paris, FR; Leuven, BE; Basel, CH; Welwyn Garden City, GB; Basel, CH

Craniocervical artery dissection in childhood – a systematic review of the literature and results from the Swiss Neuropaediatric Stroke RegistryS Heldner, M Regenyi, S Bigi, A Hackenberg, T Schmitt-Mechelke, A Datta, J Fluss, C Poloni, M El-Koussy, M Arnold, M Steinlin, B Goeggel Simonetti | Bern, CH; Zurich, CH; Luzern, CH; Basel, CH; Geneva, CH; Lausanne, CH; Bellinzona, CH

73

Posters

ePoster SSNRehab

ePoster SSS

P191

P192

P193

P194

P195

P196

P197

P198

P199

P200

P201

Functional and cognitive outcomes in patients with covert cognition during acute intensive rehabilitationJ Jöhr, F Halimi, J Pasquier, K Diserens | Lausanne, CH

Early electromyographic evaluation of the ICU-acquired Weakness in septic shock patients ventilated longer than 72 hours: preliminary resultsC Attwell, L Sauterel, J Jöhr, L Piquilloud, T Kuntzer, K Diserens | Lausanne, CH; University Hospital of Lausanne, CH

Benefits and Harms of Levodopa in Stroke Rehabilitation.S Engelter, K Wiesner, N Peters, C Traenka | Basel, CH

Salivary cortisol as a biomarker for stress level in acute patients with severe brain injuries: A feasibility studyJ Jöhr, C Attwell, P Binz, K Diserens | Lausanne, CH

Electrophysiological Correlates during Functional Proprioceptive StimulationC Schneider, M De Lucia, M Lopes Da Silva, J Jöhr, K Diserens | Lausanne, CH

Intravenous thrombolysis for acute ischemic stroke due to intracranial artery dissection: a single-center case seriesF Bernardo, S Nannoni, D Strambo, B Bartolini, P Michel, G Sirimarco | Amadora, PT; Lausanne, CH

Thrombectomy and thrombolysis of isolated posterior cerebral artery occlusion: cognitive, visual and disability outcomesD Strambo, B Bartolini, V Beaud, JP Marto, G Sirimarco, V Dunet, G Saliou, N Stefania, P Michel | Lausanne, CH

Lactate neuroprotection in permanent ischemia and in the presence of recombinant tissue plasminogen activatorL Buscemi, C Blochet, M Price, P Magistretti, H Lei, L Hirt | Lausanne, CH; Thuwal, SA

Sleep-wake Patterns after Stroke: A prospective study of 438 patientsF Alexiev, M Dekkers, S Duss, C Bassetti | Bern, CH

An usual stroke on CT-scan in an unusual patientG Saliou, X d′Ablon, M THEAUDIN, T Saliou, S Bourassi | Lausanne, CH; Deauville, FR; Mondevert, FR; Chailloué, FR

Preceding ischemic events improve early stroke severity but not outcomeP Correia, I Meyer, E Ashraf, M Amiguet, L Hirt, P Michel | Lausanne, CH

74

Post

ers

P202

P203

P204

P205

P206

P207

P208

P209

P210

Predictors for Returning to Paid Employment After Transient Ischemic Attack and Minor Ischemic StrokeCA Wicht, CF Chavan, J Annoni, P Balmer, A Humm, F Crettaz von Rotten, L Spierer, F Medlin | Marly, CH; Fribourg, CH; Lausanne, CH; Lausanne, CH

Intravenous thrombolysis for acute ischemic myelopathy : Four new cases and literature reviewP Michel, J Jankovic, V Rey-Bataillard, N Mercier, C Bonvin | Lausanne, CH; Lavigny, CH; Sion, CH

Timing is brain: The impact of endovascular therapy start time on neurological outcomeSD Hajdu, J Kaesmacher, P Michel, G Sirimarco, B Bartolini, F Puccinelli, PJ Mosimann, C Bonvin, J Niederhauser, A Eskandari, P Mordasini, J Gralla, U Fischer, G Saliou | Lausanne, CH; Bern, CH; Sion, CH; Nyon, CH

Revascularization of carotid artery occlusion using stenting versus angioplasty in endovascular management of tandem occlusion stroke.L Veunac, G Saliou, J Knebel, B Bartolini, F Puccinelli, P Michel, SD Hajdu | Lausanne, CH

Prediction of disorientation after brain damage: two versions of a taskA Adam-Darque, R Ptak, A Schnider | Geneva, CH

Immunoglobulin deficiency in multiple sclerosis – prevalence and association with disease-modifying therapy and disease courseG Zoehner, A Miclea, A Salmen, N Kamber, L Diem, C Friedli, M Bagnoud, F Ahmadi, M Briner, N Sédille-Mostafaie, K Constantinos, S Leonidas, A Chan, R Hoepner, ME Evangelopoulos | Bern, CH; Athens, GR

Quantitative magnetic resonance angiography as a potential predictor for cerebral hyperperfusion syndrome: a preliminary study.L Andereggen, S Amin-Hanjani, M El-Koussy, R Verma, K Yuki, D Schöni, K Hsieh, J Gralla, G Schroth, J Beck, A Raabe, M Arnold, R Andres, M Reinert | Aarau, CH; Chicago, US; Bern, CH; Boston, US; Lugano, CH

mTORc1 augments glucocorticosteroid efficacy in Multiple SclerosisR Hoepner, M Bagnoud, M Pistor, A Salmen, M Briner, l Schrewe, K Guse, F Ahmadi, A Chan | Bern, CH

BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar diaschisisM Sebök, CHB van Niftrik, M Piccirelli, O Bozinov, S Wegener, G Esposito, A Pangalu, A Valavanis, A Buck, A Luft, L Regli, L Regli, J Fierstra | Zurich, CH

ePoster SSS

ePoster SVNP/ASNP

ePoster YouClin

75

Posters

ePoster YouClin

P211

P212

P213

P214

P215

P216

P217

P218

P219

Electrophysiological differences between upper and lower limb movements in the human subthalamic nucleusG Tinkhauser, SA Shah, P Fischer, K Peterman, I Debove, K Nygyuen, A Nowacki, F Torrecillos, S Khawaldeh, H Tan, A Pogosyan, M Schüpbach, C Pollo, P Brown | Bern, CH; Oxford, GB

Hybrid Operating Room Settings for Treatment of Complex Dural Arteriovenous Fistulas.B Grüter, F Strange, F Burn, L Remonda, M Diepers, J Fandino, S Marbacher | Aarau, CH

Dimethyl fumarate persistence-rates and reasons for discontinuation: a retrospective study based on real world data from Denmark and SwitzerlandM Briner, C Bloch Holst, M Kant, L Diem, M Bagnoud, HB Jensen, A Chan, PB Andersen, M Góra, N Kamber, A Salmen, R Hoepner, T Sejbaek | Bern, CH; Odense, DH; Sønderborg, DK;Kolding, DK; Roskilde, DK; Slagelse, DK; Esbjerg, DK

Causes and Outcome of acute Meningitis, Meningoencephalitis and Encephalitis, a retro- and prospectiv Analysis of 215 patientsA Ungureanu, F Suter-Riniker, S Leib, C Bassetti, A Dietmann | Bern, CH

Patterns Of Care For Ruptured Aneurysms Of The Middle Cerebral Artery - Analysis Of A Swiss National Database (Swiss SOS)N Maldaner, D Bervini, P Bijlenga, K Schaller, M Roethlisberger, DW Zumofen, D Dalonzo, R Daniel, L Regli, A Weyerbrock, MN Stienen | St. Gallen, CH; Bern, CH; Geneva, CH; Basel, CH; Aarau, CH; Lausanne, CH; Zürich, CH

Is contrast media really needed for the MRI follow-up of intracranial aneurysms treated by detachable coils?J Boto, A Fitsiori, A Regnaud, L Etienne, K Lövblad, MI Vargas | Genève, CH

Linear and nonlinear interrelations show fundamentally distinct network structure in preictal intracranial EEG of epilepsy patientsM Müller, K Schindler, C Rummel | Bern, CH

Tele-rehabilitation in Post-Stroke AphasiaP Urwyler, S Gerber, N Schmidt, C Röthlisberger, S Uslu, S Perny, C Wyss, J Renggli, T Nyffeler, R Müri, T Nef | Bern, CH

The effects of transcranial direct current stimulation (tDCS) and exercise on cognition and motor in patients with chronic strokeS Kaura, MP Srivastava, S Kumaran | Delhi, IN

Spea

kers

| Ch

airs

76

Page Page

17

53

404749

53

40

4519

19

54

19

47

27

AProf. Marcel Arnold, MDInselspital BernUniversitätsklinik für NeurologieFreiburgstrasse CH-3010 Bern

BPanagiotis Bargiotas, MDInselspital BernUniversitätsklinik für Neurologie FreiburgstrasseCH-3010 Bern

Prof. Claudio Bassetti, MDInselspital BernUniversitätsklinik für NeurologieFreiburgstrasseCH-3010 Bern

Marco Battaglini, MDUniversità degli Studi di SienaDepartment of Medicine, Surgery and Neurosciencevia Banchi di Sotto 5553100 Siena, IT

Thomas Baumann, MDPraxisgemeinschaft für NeurologieNeurologieThunstrasse 95CH-3006 Bern

Prof. Jürgen Beck, MDKlinik für NeurochirurgieNeurochirurgieBreisacher Strasse 6479106 Freiburg, DE

Indrit Bègue, MDHôpitaux Universitaires GenèvePsychiatrieRue Gabrielle-Perret-Gentil 4CH-1205 Geneva

Prof. Roland Beisteiner, MDMedizinische Universität Wien Spitalgasse1090 Wien, AT

Prof. Alexandre Berney, MDCentre Hospitalier Universitaire VaudoaisPsychiatrieAv. de Beaumont 23CH-1011 Lausanne

Silke Biethahn, MDNeurozentrum Aarau NeurologieRain 34CH-5000 Aarau

PD Sandra Bigi, MDInselspital BernUniversitätsklinik für Kinderheilkunde FreiburgstrasseCH-3010 Bern

Adresses of invited speakers and chairs

PD Philippe Bijlenga, MDHôpitaux Universitaires de GenèveNeurochirurgieRue Gabrielle Perret-Gentil 4CH-1211 Geneva

Prof. Olaf BlankeUniversité de Genève, Campus BiotechNeurologieChemin des Mines 9CH-1202 Geneva

Prof. Jocelyne Bloch, MDCentre Hospitalier Universitaire Vaudois NeurochirurgieRue du Bugnon 46CH-1011 Lausanne

Colette Boex, MDHôpitaux Universitaires de GenèveNeurologieRue Gabrielle Perret-Gentil 4CH-1205 Geneva

Julia Bothmann, MDKlinik Lengg AGNeurophysiologieBleulerstrasse 60CH-8008 Zurich

Bigna Bölsterli, MDUniversitäts-Kinderspital ZürichEEG/EpilepsieSteinwiesstrasse 75CH-8032 Zurich

Prof. Thorsten Buch, MDUniversität ZürichInstitute of Laboratory Animal ScienceWagistrasse 12CH-8952 Schlieren

Sandra BucherVogelsang 84Logopädie Vogelsang 84CH-2501 Biel/Bienne

Karin Bütler, PhDARTORG Center for Biomedical Engineering ResearchGerontechnology & RehabilitationMurtenstrasse 50CH-3008 Bern

CProf. Philippe Conus, MDCentre Hospitalier Universitaire VaudoisPsychiatrieRue du Bugnon 46CH-1011 Lausanne

Giulia Cossu, MDCentre Hospitalier Universitaire VaudoisUnité de chirurgie spinaleRue du Bugnon 46CH-1011 Lausanne

19

15

49

21

41

19

27

40

38

39

23

Speakers | Chairs

77

Page Page


DMichael Diepers, MD Kantonsspital AarauNeuroradiologieTellstrasse 25CH-5001 Aarau

Karin Diserens, MDCentre Hospitalier Universitaire VaudoisNeurologieRue du Bugnon 46CH-1011 Lausanne

Prof. Kim Q. Do Cuénod, MDCHUV et Université de LausanneDépartement de psychiatrieSite de CeryCH-1008 Prilly

EMyriam Edjlali, MDCHU Sainte-AnneRue de Cabanis 175674 Paris, FR

Prof. Christian Enzinger, MDMedizinische Universität GrazAllgemeine NeurologieAuenbruggerplatz 228036 Graz, AT

Prof. Thierry Ettlin, MDReha RheinfeldenNeurologieSalinenstrasse 98CH-4310 Rheinfelden

FProf. Javier Fandino, MDKantonsspital Aarau NeurochirurgieTellstrasse 25CH-5001 Aarau

Prof. Urs Fischer, MDInselspital BernNeurologieFreiburgstrasse 10CH-3010 Bern

Katrin Frauenknecht, MDUniversitätsspital ZürichInstitut für NeuropahtologieRämistrasse 100CH-8091 Zurich

Prof. Giovanni FrisoniUniversité de Genève Centre de la mémoireRue Gabrielle-Perret-Gentil 6CH-1205 Geneva

GPD Andreas Gantenbein, MDRehaClinic Bad ZurzachNeurologieQuellenstrasse 34CH-5330 Bad Zurzach

Olivia Geisseler, MD, PhD UniversitätsSpital Zürich Neuropsychologie Rämistrasse 100 CH-8091 Zurich

Prof. Elke Gizewski, MDMedizinische Universität InnsbruckUniversitätsklinik für NeuroradiologieAnichstrasse 356020 Innsbruck, AT

Markus Gschwind, MDKantonsspital AarauNeurologieTellstrasse 25CH-5001 Aarau

Prof. Adrian Guggisberg, MDHôpitaux Universitaires GenèveNeurorééducationRue Gabrielle-Perret-Gentil 4CH-1205 Geneva

Prof. phil Klemens Gutbrod, MDInselspital BernNeuropsychologie Freiburgstrasse 10CH-3010 Bern

Prof. Raphael Guzman, MD Universitätsspital BaselNeurochirurgieSpitalstrasse 21/Petersgraben 4CH-4031 Basel

HProf. Yoon Yonsei Ha, MDYonsei University 50-1 Yonsei-Ro, Seodaemun-Gu120-750 Seoul, South Korea

Prof. Mark Hallett, MD National Institutes of Health10 Center DriveMD 20892-1428, Bethesda, USA

Susanne Hartmann-Fussenegger, MDKantonsspital St. GallenPalliativzentrumRorschacher Strasse 95CH-9007 St. Gallen

David M. Hasan, MDUniversity of Iowa Health CareNeurosurgery2000 Hawkins DrIowa City, IA 52242, USA

Prof. Elke Hattingen, MDUniversitätsklinikum FrankfurtInstitut für NeuroradiologieTheodor-Stern-Kai 760590 Frankfurt am Main, DE

19

23

27

19

53

4923

273839

17

35

49

47

21

53

19

38

19

51

40

5354

27

19

54

Spea

kers

| Ch

airs

78


Page Page40

23

21

53

49

15

55

39

45

15

PD Oliver Hausmann, MDKlinik St. AnnaNeurochirurgieSt. Anna Strasse 32CH-6006 Luzern

Prof. Katharina Henke, PhDUniversität BernInstitut für PsychologieFabrikstrasse 8CH-3012 Bern

Prof. Christian W. Hess, MDAlpenstrasse 28CH-3084 Wabern bei Bern

Evi Holzknecht, MDMedizinische Universität InnsbruckNeurologieChristoph-Probst-Platz6020 Innsbruck, AT

Prof. Friedhelm Christoph Hummel, MDSwiss Federal Institute of Technology EPFL Campus BiotechChemin des Mines 9CH-1202 Geneva

IProf. Adrian IonescuEcole Polytechnique fédérale de LausannenanolabStation 11 CH-1015 Lausanne

Anja IschebekUniversität GrazInstitut für PsychologieUniversitätsplatz 38010 Graz, AT

JProf. Peter Jakob, MDUniversität WürzburgAm Hubland97074 Würzburg, DE

Prof. Olav Jansen, MDUniversitätsklinikum Schleswig-Holstein Klinik für Radiologie und Neuroradiologie Arnold-Hel-ler-Strasse 324105 Kiel, DE

KProf. Walter KarlenETH ZürichGesundheitswissenschaft und TechnologieLengghalde 5CH-8092 Zurich

Prof. Emanuela Keller, MDUniversitätsSpital ZürichKlinik für NeurochirurgieRämistrasse 100CH-8091 Zurich

Philipp Kickingereder, MDUniversitätsKlinikum HeidelbergNeuroradiologieIm Neuenheimer Feld 40069120 Heidelberg, DE

PD Eberhard Kirsch, MDBethesda SpitalRadiologieGellertstrasse 144CH-4052 Basel

Prof. Ramin Khatami, MDKlinik und Pflegezentrum BarmelweidNeurologieCH-5017 Barmelwaid

PD Andrea Klein, MDUniversitäts-Kinderspital beider Basel NeuropädiatrieSpitalstrasse 33CH-4056 Basel

Prof. Andreas Kleinschmidt, MD Hôpitaux Universitaires de GenèveNeurologieRue Gabrielle-Perret-Gentil 4CH-1211 Geneva

PD Karl Kothbauer, MDLuzerner KantonsspitalNeurochirurgieCH-6000 Luzern

PD Zsolt Kulcsàr, MDUniversitätsSpital ZürichKlinik für NeuroradiologieFrauenklinikstrasse 10CH-8091 Zurich

Prof. Thierry Kuntzer, MDCentre Hospitalier Universitaire VaudoisNeurologieRue du Bugnon 21CH-1011 Lausanne

LAgustina Lascano, MDHôpitaux Universitaires de GenèveNeurologieRue Gabrielle-Perret-Gentil CH-1201 Geneva

19

54

40

39

38

47

21

17

1738

41

Speakers | Chairs

79


Page PageAnja Leiber, MDOstschweizer KinderspitalNeuropädiatrieClaudiusstrasse 6CH-9006 St. Gallen

Prof. Karl-Olof Lövblad, MD Hôpitaux Universitaires de GenèveNeuroradiologieRue Gabrielle-Perret-Gentil 4CH-1205 Geneva

Prof. Andres Lozano, MDUniversity of Toronto Neurosurgery399 Bathurst StreetToronto M5T 2S8, CA

MProf. Georgios Mantokoudis, MDInselspital BernHNO KlinikFreiburgstrasseCH-3010 Bern

PD Serge Marbacher, MDKantonsspital AarauNeurochirurgieTellstrasse 25CH-5001 Aarau

Pierre Mégevand, MD, PhDHôpitaux Universitaires GenèveNeurologieRue Gabrielle-Perret-Gentil 4CH-1211 Geneva

Prof. Torstein Meling, MDHôpitaux Universitaires GenèveNeurochirurgieRue Gabrielle-Perret-Gentil 4CH-1211 Geneva

Prof. Vitor Mendes Pereira, MDToronto Western Hospital/University of TorontoSurgery/Radiology399 Bathurst St.Toronto, ON, M5T 2S8, CA

Prof. Andreas Meyer-Lindenberg, MDZentralinstitut für Seelische GesundheitJ 568159 Mannheim, DE

PD Lars Michels, MDUniversitätsSpital ZürichNeuroradiologieFrauenklinikstrasse 10CH-8091 Zurich

PD Thorsten Mikoteit, MDSolothurner Spitäler AG Psychiatrie, Psychotherapie und PsychosomatikSchöngrünstrasse 36A CH-4500 Solothurn

Prof. Martin Monti, MDUniversity of California Los AngelesDepartment of Psychology7461E Franz HallCA 90095 Los Angeles, US

NProf. Krassen Nedeltchev, MDKantonsspital AarauNeurologieTellstrasse 25CH-5001 Aarau

Prof. Tobias Nef Universität Bern ARTORG Center for Biomedical Murtenstrasse 50 CH-3008 Bern

Jan Novy, MDCentre hospitalier universitaire vaudoisNeurologieRue du Bugnon 46CH-1011 Lausanne

Prof. Thomas Nyffeler, MDLuzerner KantonsspitalNeurorehabilitationSpitalstrasseCH-6000 Luzern

PPD Jens Petersen, MDNeurozentrum BernKlinik für NeurologieSchänzlistrasse 33CH-3013 Bern

Hans-Albert Pihan, MDSpitalzentrum BielNeurologieVogelsang 84CH-2501 Biel/Bienne

Ferran Prados CarrascoUniversity College LondonComputer ScienceGower StreetLondon, UK

Etienne Pralong, MDCentre hospitalier universitaire vaudoisNeurochirurgieRue du Bugnon 46CH-1011 Lausanne

41

153949

54

47

39

49

29

49

39

45

33

54

27

38

49

49

27

40

53

21

Spea

kers

| Ch

airs

80


Page Page1923

273945

39

39

39

49

15

49

41

51

47

Prof. Radek Ptak, MDHôpitaux Universitaires de GenèveNeurorehabilitationAv. de Beau-Séjour 26CH-1206 Geneva

RProf. Andreas Raabe, MDInselspital BernNeurochirurgieFreiburgstrasse 16CH-3010 Bern

Prof. Luca Remonda, MDKantonsspital AarauNeuroradiologieTellstrasse 25CH-5001 Aarau

Prof. Michael Reinert, MDOspedale Regionale di Lugano, civico e italianoNeurochirurgieVia Tesserete 46CH-6900 Lugano

Javier M. Romero, MDMassachussetts General HospitalFruit Street 55MA 02114 Boston, USA

Tomas Ros, PhDUniversité de GenèveCampus BiotechChemin des Mines 9CH-1202 Geneva

Prof. Kai Rösler, MDNeuroZentrum BaselMarktplatz 5CH-4001 Basel

Prof. Andrea Rossetti, MDCentre Hospitalier Universitaire VaudoisNeurologieRue du Bugnon 46CH-1011 Lausanne

Prof. Stephan Rüegg, MDUniversitätsspital Baselklinische NeurophysiologieSpitalstrasse 21/Petersgraben 4CH-4031 Basel

Stefanie RuhMedtronic (Schweiz) AGTalstrasse 9CH-3053 Münchenbuchsee

SProf. Peter Sandor, MDRehaClinic AGNeurologieQuellenstrasse 34CH-5330 Bad Zurzach

Prof. Karl Schaller, MDHôpitaux Universitaires de GenèveNeurochirurgieRue Gabrielle Perret-Gentil 4CH-1205 Geneva

PD Christoph Schankin, MDInselspital BernNeurologieFreiburgstrasseCH-3010 Bern

Olivier Scheidegger, MDInselspital BernNeurologieFreiburgstrasseCH-3010 Bern

Prof. Kaspar Schindler, MDInselspital BernNeurologieFreiburgstrasseCH-3010 Bern

Jürgen SchmidtHirslanden Klinik LindeLeiter OP-BereichBlumenrain 105CH-2501 Biel

Prof. Armin Schnider, MDHôpitaux Universitaires de GenèveNeurorééducationAv. de Beau-Séjour 26CH-1211 Geneva

Menno Schoonheim, MDVU University Medical CenterDe Boelelaan 11171081 Amsterdam, NL

PD Kathleen Seidel, MDInselspital BernNeurochirurgieFreiburgstrasseCH-3010 Bern

Andrea SerinoCentre Hospitalier Universitaire VaudoisClinical NeuroscienceRue du Bugnon 21CH-1011 Lausanne

PD Arseny Sokolov, MDCentre Hospitalier Universitaire VaudoisNeurologieRue du Bugnon 46CH-1011 Lausanne

Samuel Sommaruga, MD Hôpitaux Universitaires Genève Neurochirurgie Rue Gabrielle Perret-Gentil 4 CH-1205 Geneva

151945

47

1738

49

51

23

53

2151

15

38

45

Speakers | Chairs

81


Page PageIstvan StankoUniversitätsspital BaselFachpflegeSpitalstrasse 21/Petersgraben 4CH-4031 Basel

PD Lennart Henning Stieglitz, MDUniversitätsSpital ZürichNeurochirurgieFrauenklinikstrasse 10CH-8091 Zurich

PD Martin Stienen, MD UniversitätsSpital ZürichNeurochirurgieFrauenklinikstrasse 10CH-8091 Zurich

Prof. Christoph Stippich, MDUniversitätsspital Zürich Neuroradiologie Frauenklinikstrasse 10CH-8091 Zurich

Prof. Andreas Straube, MDKlinikum der Universität MünchenNeurologieMarchioninistr. 1581377 München, DE

Prof. Dominik Straumann, MDUniversitätsSpital ZürichNeurologieFrauenklinikstrasse 26CH-8091 Zurich

TMehdi TaftiUniversité de LausannePhysiologieRue du Bugnon 7CH-1005 Lausanne

PD Alexander A. Tarnutzer, MDKantonsspital BadenNeurologieIm Ergel 1CH-5404 Baden

Prof. Barbara Tettenborn, MDKantonsspital St. GallenNeurologieRorschacher Strasse 95CH-9007 St. Gallen

VPD Philipp Valko, MDUniversitätsSpital ZürichNeurologieRämistrasse 100CH-8091 Zurich

Prof. Johan Van Goethem, MDUniversity AntwerpenNeuroradiologieWilrijkstraat 102650 Edegem, BE

Prof. Maria Isabel Vargas, MDHôpitaux Universitaires de GenèveNeuroradiologieRue Gabrielle-Perret-Gentil 4CH-1205 Geneva

WFranca Wagner, MDInselspital Berndiagn. & interv. NeuroradiologieFreiburgstrasse 10CH-3010 Bern

PD Daniel Waldvogel, MDKlinik St. AnnaNeurologieSt. Anna Strasse 32CH-6006 Luzern

Prof. Sebastian Walther, MDUniversitätsklinik für Psychiatrie und PsychotherapieMurtenstrasse 21CH-3008 Bern

Prof. Isabel Wanke, MDKlinik Hirslanden AGNeuroradiologieWitellikerstrasse 40CH-8032 Zurich

Prof. Roland Wiest, MDInselspital BernNeurologieFreiburgstrasse 10CH-3010 Bern

Benedikt WiestlerKlinikum rechts der Isa der Technischen Universität MünchenNeuro-Kopf-ZentrumIsmaninger Strasse 2281675 München, DE

ZProf. Werner Z'Graggen, MDInselspital BernNeurochirurgieFreiburgstrasse 16CH-3010 Bern

Rebekka Zimmermann, MDInselspital BernNeurologieFreiburgstrasse 10CH-3010 Bern

51

4151

21

174553-55

45

47

3940

47

27

21

27

3945

45

40

39

29

384553

54

1951

47

SOLUTIONS INDIVIDUELLESPOUR PATIENTS SEP

Biogen Switzerland AG, Zählerweg 6, CH-6300 ZougDès avril 2019: Biogen Switzerland SA, Neuhoferstrasse 30, CH-6340 Baar Biogen-03591_12.2018

BIOG613 Multiple_Choices_Fachinserat_FR_148x210_3mm V02.indd 1 17.04.19 13:21

Speakers | Chairs

83


4666a1825491636483013b12c13a66b47502765332447351965543a5612b10382639511417

1a medical agAbbVie AGAlexion Pharma GmbHAllergan AGAlnylamB. Braun Medical AG, AesculapBaxter AGBiocodexBiogen Switzerland AGBioprojet PharmaBrainlab Sales GmbHBurkart Medizintechnik AGCarl Zeiss AGCelgene GmbHCerenovus, Johnson & Johnson AGCodman Specialty SurgicalCSL BehringDesitin Pharma GmbHEISAI Pharma AGEli Lilly Suisse (SA)Fehling Instruments GmbH & Co. KGGE Healthcare AGGrünenthal Pharma AGHealth Solutions & Support AGicotec aginomed Medizintechnik GmbHIntermediate CareBerger Medizintechnik GmbHKedrion Swiss SarlLeica Microsystems (Schweiz) AGMedacta InternationalMediService AGMeditrend SAMedtronic (Schweiz) AGMerck (Schweiz) AGMerz Pharma (Schweiz) AG

Opening hours of the industrial exhibition:Wednesday, 23.10.2019 09:30-17:30Thursday, 24.10.2019 08:00-17:15Friday, 25.10.2019 08:15-16:00

Alphabetical orderNo NoCompany Company

4125b26a2852203156444374912a53231145a21 + 22543b63341545b25a4285712940

MicroVention Deutschland GmbHMitsubishi-Tanabe-PharmaMyoSwiss AGNeurolite AGNeuroswiss AGNovartis Pharma Schweiz AGNovocure GmbHNuVasive Switzerland GmbHOlea MedicalOlympus Schweiz AGParadigm Spine Switzerland AGPenumbra Europe GmbHPromedics GmbHRapid MedicalRoche Pharma (Schweiz) AGrumed gmbhSandoz Pharmaceuticals AGSanofi GenzymeSarepta TherapeuticsSchweizerische Epilepsie-LigaSPINEART SASpirig HealthcareStöckli Medical AGStryker Osteonics SATakeda Pharma AGTechno ConceptTeva Pharma AGUCB-Pharma AGVostra GmbHZambon Svizzera SAZimmer GmbH

Spea

kers

| Ch

airs

84


123456789101112a12b12c13a13b14151516171819202122232425a25b2626a272829303334

Vostra GmbHAllergan AGNovocure GmbHFehling Instruments GmbH & Co. KGSarepta Therapeuticsicotec agGE Healthcare AGTeva Pharma AGB. Braun Medical AG, AesculapLeica Microsystems (Schweiz) AGrumed gmbhPromedics GmbHKedrion Swiss SarlBurkart Medizintechnik AGCarl Zeiss AGBrainlab Sales GmbHMerck (Schweiz) AGNuVasive Switzerland GmbHStöckli Medical AGBaxter AGMerz Pharma (Schweiz) AGAlexion Pharma GmbHHealth Solutions & Support AGNovartis Pharma Schweiz AGSanofi GenzymeSanofi GenzymeRoche Pharma (Schweiz) AGEli Lilly Suisse (SA)Takeda Pharma AGMitsubishi-Tanabe-PharmaMediService AGMyoSwiss AGCSL BehringNeurolite AGZambon Svizzera SABioprojet PharmaEISAI Pharma AGSpirig Healthcare

353637383940414243a43b4445a45b46474849505152535455565763646566a66b

Grünenthal Pharma AGBiocodexParadigm Spine Switzerland AGMedacta InternationalMeditrend SAZimmer GmbHMicroVention Deutschland GmbHTechno ConceptIntermediate CareSchweizerische Epilepsie-LigaOlympus Schweiz AGSandoz Pharmaceuticals AGStryker Osteonics SA1a medical agCerenovus, Johnson & Johnson AGBiogen Switzerland AGPenumbra Europe GmbHCodman Specialty SurgicalMedtronic (Schweiz) AGNeuroswiss AGRapid MedicalAlnylaminomed Medizintechnik GmbHBerger Medizintechnik GmbHUCB-Pharma AGSPINEART SAOlea MedicalDesitin Pharma GmbHAbbVie AGCelgene GmbH

By booth numberNo NoCompany Company

85

Exhibition Plan

Entrance

Plenum

Secretariat

Catering

Catering

Cate

ring

CateringCate

ring

CongressLounge

23

24 25b

66a

48 49

5150

5253

5455

5657

47

66b

22

19

15

4

610

3

1112c

12a12b

13a13b

21

5

16

18

17

20

14

21

6564

63

25a

26a

79 8

26

2728

2930

35

3334

3738

3940

4144

4243

b43

a

36

45a

45b

46

NO5

1368

01/

2019

RRMS = Relapsing Remitting Multiple Sclerosis / schubförmig remittierende Multiple Sklerose.Bei der abgebildeten Person handelt es sich nicht um eine reelle Patientin, sondern um ein Model. * Therapie-naive und vorbehandelte Patienten

Referenzen: 1 Chitnis T et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med 2018;379:1017-27. 2 GILENYA®

(Fingolimod) Fachinformation, Stand der Information: November 2018, www.swissmedicinfo.ch. 3 Kappos L, O’Connor P, Radue EW et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology 2015;84:1582-91. 4 Agius M, Meng X, Chin P et al. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom. CNS Neurosci Ther 2014;20:446 -51. 5 Ziemssen T et al. PANGAEA: 5 years effectiveness of fingolimod in daily clinical practice. Poster presented at the 70th Annual meeting of the American Academy of Neurology, 21–27 April 2018. Poster no 6.393. 6 Brinkmann V et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010 Nov;9(11):883-97. 7 Mehling M et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 Oct 14;71(16):1261-7. 8 Novartis Q3 2018 Interim Financial Report, Verfügbar unter: https://www.novartis.com/investors/financial-data/quarterly-results#ui-id-1=0, zuletzt eingesehen: 28. November 2018. 9 Clinicaltrials, Multiple Sclerosis + fingolimod, verfügbar unter: https://www.clinicaltrials.gov/ct2/results?cond=Multiple+Sclerosis&term=fingolimod&cntry=&state=&city=&dist=, zuletzt eingesehen: 1. Dezember 2018.

GILENYA® (Fingolimod) gekürzte Fachinformation Z: Kapseln zu 0.25 mg oder 0.5 mg Fingolimod. I: Gilenya ist zur Behandlung von Erwachsenen, Jugendlichen und Kindern ab 10 Jahren mit schubförmig remittierend verlaufender Multipler Sklerose (MS) zur Reduzierung der Schubhäufigkeit und zur Verzögerung des Fortschreitens der Behinderung indiziert. D: Erwachsene 0.5 mg 1 x täglich oral Kinder und Jugendliche mit einem Körpergewicht von 40 kg 0.25 mg 1 x täglich oral Kinder und Jugendliche mit einem Körpergewicht von mehr als 40 kg: 0.5 mg 1 x täglich oral. KI: Myokardinfarkt, instabile Angina pectoris, Schlaganfall/TIA, akut dekompensierte Herzinsuffizienz, Herzinsuffizienz NYHA-Klasse III/IV • Schwere Herzrhythmusstörungen • AV-Block 2. Grades vom Typ Mobitz II oder ein AV-Block 3. Grades oder Sick-Sinus-Syndrom, sofern nicht Schrittmacher-versorgt • QTc-Intervall ≥ 500 ms bei Baseline • Immundefizienzsyndrom • Erhöhtes Risiko für opportunistische Infektionen • Schwere aktive Infektionen, aktive chronische Infektionen • Aktive maligne Erkrankungen • Mittlere/schwere Leberinsuffizienz/Leberzirrhose (Child-Pugh-Klasse B und C) • Makulaödem • Schwangerschaft, Stillzeit • Überempfindlichkeit gegenüber Wirk-/Hilfsstoffe. VM: Bei allen Patienten nach Ersteinnahme: 6-stündige kardiale Überwachung auf Symptome einer Bradykardie sowie auf atrioventrikuläre Überleitungsstörungen. Bei Patienten mit kardialen Auffälligkeiten in den ersten 6 Stunden nach Ersteinnahme, kardialen Vorerkrankungen, herzfrequenz-verlangsamender Therapie oder QT-Intervall Verlängerungen sollte kardiologische Überwachung verlängert werden (Einzelheiten zum kardialen Monitoring s. www.swissmedicinfo.ch). • Grosses Blutbild (BB) inkl. Diff-BB vor Einleitung der Behandlung, in Monat 3 und danach regelmässig (mind. jährlich), sowie bei Anzeichen einer Infektion. Bei Gesamtlymphozytenzahl < 0.1x109/l Behandlung pausieren. Bei Gesamtlymphozytenzahl <0.2x109/l Diff-BB mind. alle 3 Monate. Bei schweren aktiven Infektionen oder aktiven chronischen Infektionen mit Behandlung abwarten. • Fälle von PML (progressive multifokale Leukenzephalopathie) traten ohne Vorbehandlung mit Natalizumab nach einer ungefähren Behandlungsdauer von 2–3 Jahren auf. MRI-Aufnahme ist zu Beginn der Behandlung empfohlen. Bei Verdacht auf PML: MRI-Untersuchung durchführen und die Behandlung aussetzen, bis Infektion ausgeschlossen werden kann. • Fälle von Kryptokokkeninfektionen einschliesslich Kryptokokkenmeningitis traten nach einer Behandlung von ungefähr 2–3 Jahren auf. Patienten mit Verdacht auf Kryptokokkenmeningitis sollten umgehend diagnostisch beurteilt werden. • Augenärztliche Untersuchung vor Beginn und nach 3 –4 monatiger Therapie. Visusuntersuchungen alle 6 Monate. • Bestimmung der Leberwerte vor Beginn und 1, 3, 6, 9 und 12 Monate nach Beginn der Therapie, im weiteren Verlauf periodisch. • Blutdruck regelmässig kontrollieren. • Bei Verdacht auf posteriores reversibles Enzephalopathie-Syndrom Gilenya absetzen. • Pulmonologische Untersuchung bei symptomatischen Patienten. • Fälle von malignen kutanen Neoplasien (z. B. Basalzellkarzinome, Melanome) sind unter der Behandlung mit Gilenya aufgetreten. Eine regelmässige dermatologische Überwachung ist empfohlen. • Vorsicht bei Umstellung von anderen immunsuppressiven/immunmodulierenden Therapien auf Gilenya. Bei Natalizumab und Teriflunomid Halbwertszeit berücksichtigen. Umstellung von Alemtuzumab nicht empfohlen. IA: Antineoplastische, immunsuppressive oder immunmodulierende Therapien (inkl. Kortikosteroide) • Umstellung von lang wirkenden Immuntherapeutika (Natalizumab, Teriflunomid oder Mitoxantron) • Impfstoffe • Betablocker, Calciumkanalblocker und andere Substanzen, die die Herzfrequenz verlangsamen können • Ketoconazol • Carbamazepin. UW: Sehr häufig: Grippale Virusinfektionen, Sinusitis, Kopfschmerzen, Husten, Durchfall, Rückenschmerzen, erhöhte Leberenzyme • Häufig: Bronchitis, Herpes Zoster, Tinea Versicolor, Basaliom, Leukopenie, Lymphopenie, Schwindel, Migräne, Verschwommensehen, Bradykardie, atrioventrikuläre Blocks, Hypertonie, Atemnot, Ekzem, Pruritus, Asthenie, erhöhte Bluttriglyzeride, Depressionen • Gelegentlich: Pneumonie, Melanome, Krampfanfälle, Makulaödem, Depressive Verstimmungen • Selten und sehr selten: s. www.swissmedicinfo.ch P: Kapseln zu 0.25 mg: 7 und 28 oder 0.5 mg: 28 und 98. Verkaufskategorie: B. Weitere Informationen: www.swissmedicinfo.ch. Stand der Information November 2018, V15 Novartis Pharma Schweiz AG, Risch; Adresse: Suurstoffi 14, 6343 Rotkreuz, Tel. 041 763 71 11

NEU auch für junge

Patienten ab 10 Jahren2

GILENYA® – Ideal für den

frühen RRMS-Therapiestart1–4

84 % Schubreduktion nach 5 Jahren5,*

Einzigartiger, reversibler

Wirkmechanismus2,6,7

261’000 weltweit therapierte Patienten,8

76 klinische Studien9

swiss federation of clinical neuro-societies

Documents